11 March 2022
EMA/CHMP/95406/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 24-27 January 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See January 2022 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 24-27 January 2022.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present remotely). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified. The views of the EEA member states will not be reflected separately, unless divergent to the CHMP opinion.

1.2. Adoption of agenda

CHMP agenda for 24-27 January 2022.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 13-16 December 2021.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 17 January 2022.

The CHMP adopted the minutes of the December Plenary meeting as well as the minutes from the January PROM meeting.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. gefapixant - EMEA/H/C/005884

treatment of refractory or unexplained chronic cough

Scope: Oral explanation

Action: Oral explanation to be held on 26 January 2022 16:00

List of Outstanding Issues adopted on 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.2. gefapixant - EMEA/H/C/005476

treatment of refractory or unexplained chronic cough

Scope: Oral explanation

Action: Oral explanation to be held on 26 January 2022 16:00

List of Outstanding Issues adopted on 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.3. betulae cortex dry extract (5-10: 1); extraction solvent: n-heptane 95% (w/w) - Orphan - EMEA/H/C/005035

Amryt Pharmaceuticals DAC; Treatment to achieve accelerated healing of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients from birth onwards.

Scope: Possible oral explanation/ Proposal for AHEG

Action: Possible oral explanation to be held on 25 January 2022 14:00

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 22.07.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.4. Paxlovid – (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir – EMEA/H/C/005973

Pfizer Europe MA EEIG; treatment of COVID-19

Scope: Possible oral explanation/opinion

Action: Possible oral explanation to be held on 25 January 2022 16:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

2.4.1. Stresam and generics – etifoxine (hydrochloride) - EMEA/H/A-31/1509

Biocodex

Referral Rapporteur: John Joseph Borg, Co-Rapporteur: Simona Badoi (collaboration with Bulgaria)

Scope: Oral explanation

Action: Oral explanation to be held on 24 January 2022 at 14:00

ANSM has triggered a referral under Article 31 of Directive 2011/83/EC to review the B/R balance of etifoxine containing products, in light of the new results from the AMETIS study.

The CHMP agreed that an oral explanation was not needed at this time.

See 10.6

2.4.2. Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506

International Drug Development France

Re-examination Referral Rapporteur: Ewa Balkowiec Iskra, Re-examination Co-Rapporteur: Janet Koenig

Initial assessment: Referral Rapporteur: Kristine Moll Harboe, Co-Rapporteur: Paula Boudewina van Hennik

Scope: Oral explanation

Action: Oral explanation to be held on 24 January 2022 at 16:00

Summary: Decentralised Procedure number: DK/H/3106/001/DC, notification by the Danish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MS is of the opinion that therapeutic equivalence has not been demonstrated between the test and the reference product.

An oral explanation was held on Monday, 24 January 2022. The presentation by the applicant focused on the clinical data in support of the application.

See 10.7

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - PRIME - Orphan - ATMP - EMEA/H/C/004731

Bristol-Myers Squibb Pharma EEIG; treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 08.10.2021, 16.04.2021. List of Questions adopted on 06.11.2020.

Based on the draft opinion prepared by the CAT, the CHMP adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that the two active substances (CD8+ cells and CD4+ cells) which are covered under a single INN, lisocabtagene maraleucel are new active substances, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 24 January 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.2. Dasatinib Accord - dasatinib - EMEA/H/C/005446

Accord Healthcare S.L.U.; treatment of leukaemia

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Sprycel, Duplicate of Dasatinib Accordpharma

List of Outstanding Issues adopted on 25.02.2021, 25.06.2020. List of Questions adopted on 17.10.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 26 January 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.3. Dasatinib Accordpharma - dasatinib - EMEA/H/C/005317

Accord Healthcare S.L.U.; treatment of leukaemia

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Sprycel

List of Outstanding Issues adopted on 25.02.2021, 25.06.2020. List of Questions adopted on 17.10.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 26 January 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.4. Paxlovid – (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir – EMEA/H/C/005973

Pfizer Europe MA EEIG; treatment of COVID-19

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendations dated 27 January 2022.

The summary of opinion was circulated for information.

3.1.5. Sondelbay - teriparatide - EMEA/H/C/005827

Accord Healthcare S.L.U.; treatment of osteoporosis

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.6. Stimufend - pegfilgrastim - EMEA/H/C/004780

Fresenius Kabi Deutschland GmbH; treatment of neutropenia

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 17.09.2020.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendations dated 26 January 2022.

The summary of opinion was circulated for information.

3.1.7. Vildagliptin/Metformin hydrochloride Accord - vildagliptin / metformin hydrochloride - EMEA/H/C/005738

Accord Healthcare S.L.U.; treatment of type 2 diabetes mellitus

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Eucreas

List of Outstanding Issues adopted on 16.12.2021, 16.09.2021. List of Questions adopted on 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. amifampridine - EMEA/H/C/005839

treatment of Lambert-Eaton Myasthenic Syndrome

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. leuprorelin - EMEA/H/C/005034

indicated for the treatment of hormone dependent advanced prostate cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.07.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. dimethyl fumarate - EMEA/H/C/006039

treatment of multiple sclerosis

Scope: List of outstanding issues

Action: For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. dimethyl fumarate - EMEA/H/C/005956

treatment of multiple sclerosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.10.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. dimethyl fumarate - EMEA/H/C/005955

treatment of multiple sclerosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.10.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. dimethyl fumarate - EMEA/H/C/006042

treatment of multiple sclerosis

Scope: List of outstanding issues

Action: For adoption

The Committee was reminded of the status of this application and its remaining outstanding.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. trastuzumab - EMEA/H/C/005880

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: List of outstanding issues

Action: For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. betulae cortex dry extract (5-10: 1); extraction solvent: n-heptane 95% (w/w) - Orphan - EMEA/H/C/005035

Amryt Pharmaceuticals DAC; Treatment to achieve accelerated healing of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients from birth onwards.

Scope: List of outstanding issues/ Proposal for AHEG

Action: For adoption

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 22.07.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

The CHMP agreed to consult an Ad-hoc expert group (AHEG) and adopted a list of questions to this group.

3.2.9. artesunate - Orphan - EMEA/H/C/005718

B And O Pharm; Treatment of severe malaria

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 16.09.2021, 22.07.2021. List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

3.2.10. gefapixant - EMEA/H/C/005884

treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

3.2.11. tebentafusp - Orphan - EMEA/H/C/004929

Accelerated assessment

Immunocore Ireland Limited; treatment of uveal melanoma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 09.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.12. budesonide, micronised - Orphan - EMEA/H/C/005653

Calliditas Therapeutics AB; treatment of primary immunoglobulin A (IgA) nephropathy

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. gefapixant - EMEA/H/C/005476

treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

3.2.14. capmatinib - EMEA/H/C/004845

treatment of non-small cell lung cancer (NSCLC)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.15. insulin aspart - EMEA/H/C/005635

treatment of diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.16. trastuzumab - EMEA/H/C/005066

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

3.2.17. doxorubicin - EMEA/H/C/005320

treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 26.03.2020. List of Questions adopted on 17.10.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. vutrisiran - Orphan - EMEA/H/C/005852

Alnylam Netherlands B.V.; treatment of hereditary transthyretin-mediated amyloidosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. mavacamten - EMEA/H/C/005457

treatment of symptomatic obstructive hypertrophic cardiomyopathy

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions. The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the LoQ.

3.3.3. dimethyl fumarate - EMEA/H/C/005963

treatment of multiple sclerosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

3.3.4. pegfilgrastim - EMEA/H/C/005810

Treatment of neutropenia

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. maralixibat - Orphan - EMEA/H/C/005857

Mirum Pharmaceuticals International B.V.; Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. mosunetuzumab - Orphan - EMEA/H/C/005680

Accelerated assessment

Roche Registration GmbH; refractory follicular lymphoma (FL)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. relatlimab / nivolumab - EMEA/H/C/005481

indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents (12 years and older and weighing at least 40 kg).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. efbemalenograstim alfa - EMEA/H/C/005828

Reduction in the duration of neutropenia and the incidence of febrile neutropenia.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. teriflunomide - EMEA/H/C/005962

treatment of multiple sclerosis (MS)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. ranibizumab - EMEA/H/C/005617

treatment of neovascular age-related macular degeneration (AMD)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.11. ganaxolone - Orphan - EMEA/H/C/005825

Marinus Pharmaceuticals Emerald Limited; treatment of epileptic seizures associated with cyclin dependent kinase-like 5 deficiency disorder (CDD)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. eptacog alfa (activated) - EMEA/H/C/005547

treatment of bleeding episodes and for the prevention of bleeding

Scope: Letter from the applicant dated 20.12.2021 requesting an extension to the clock stop to respond to the list of questions adopted in November 2021.

List of Questions adopted on 11.11.2021

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in November 2021.

3.4.2. voclosporin - EMEA/H/C/005256

indicated in combination with background immunosuppressive therapies for the treatment of adult patients with class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

Scope: Letter from the applicant dated 13.01.2022 requesting an extension to the clock stop to respond to the list of questions adopted in November 2021.

Action: For adoption

List of Questions adopted on 11.11.2021

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in November 2021.

3.4.3. arimoclomol - Orphan - EMEA/H/C/005203

Orphazyme A/S; treatment of Niemann-Pick disease type C (NPC)

Scope: List of experts for an ad-hoc expert group meeting.

Action: For information

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 25.03.2021.

The CHMP noted the draft list of experts for the ad-hoc expert group (AHEG) meeting.

Post meeting note: The list of experts was adopted via written procedure on 16.02.2022.

3.4.4. adrenaline - EMEA/H/C/005584

For the emergency treatment of allergic reactions, including anaphylaxis

Scope: Update on the procedure.

Action: For discussion

List of Questions adopted on 25.03.2021.

The CHMP noted the status of this procedure.

3.4.5. autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: Request from the company for an extension to the clock stop to respond to the list of outstanding issues adopted in July 2021.

Action: For information

List of Outstanding Issues adopted on 16.07.2021. List of Questions adopted on 22.01.2021.

The CHMP endorsed the timetable as adopted by CAT, which was shorter than requested by the applicant to the list of outstanding issues adopted in July 2021.

3.4.6. palovarotene - Orphan - EMEA/H/C/004867

Ipsen Pharma; Treatment of fibrodysplasia ossificans progressiva

Scope: Letter from the applicant dated 14.01.2022 requesting an extension to the clock stop to respond to the list of questions adopted in September 2021

Action: For adoption

List of Questions adopted on 16.09.2021

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in September 2021.

3.4.7. thalidomide - EMEA/H/C/005715

treatment of multiple myeloma

Scope: Letter from the applicant dated 14.01.2022 requesting an extension to the clock stop to respond to the list of questions adopted in September 2021.

Action: For adoption

List of Questions adopted on 16.09.2021

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in September 2021.

3.4.8. lonafarnib - Orphan - EMEA/H/C/005271

EigerBio Europe Limited; treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

Scope: Letter from the applicant dated 18.01.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in December 2021.

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021, 16.09.2021, 25.02.2021. List of Questions adopted on 23.07.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in December 2021.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Ipique - bevacizumab - EMEA/H/C/005433

Rotterdam Biologics B.V.; indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes.

Scope: List of questions to the AHEG

Action: For adoption

Well-established use application (Article 10a of Directive No 2001/83/EC)

Opinion adopted on 11.11.2021. List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 17.09.2020.

The CHMP agreed to consult an Ad-hoc expert group (AHEG) and adopted a list of questions to this group together with a list of experts.

3.5.2. Aduhelm - aducanumab - EMEA/H/C/005558

Biogen Netherlands B.V.; Alzheimer's disease

Scope: Call for re-examination rapporteurs

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

The CHMP noted the call for re-examination rapporteurs.

3.6. Initial applications in the decision-making phase

3.6.1. Padcev - enfortumab vedotin - EMEA/H/C/005392

Astellas Pharma Europe B.V.; treatment of locally advanced (LA) or metastatic urothelial cancer (mUC)

Scope: Update on the status of this application.

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 14.09.2021. List of Questions adopted on 22.06.2021.

The CHMP noted the status of this application.

The Committee adopted a list of questions with a specific timetable.

3.6.2. Yselty - linzagolix choline - EMEA/H/C/005442

ObsEva Ireland Ltd; for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids

Scope: Update on the status of this application.

Action: For discussion

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 11.11.2021, 16.09.2021. List of Questions adopted on 22.04.2021.

The CHMP noted the status of this application.

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Abylqis - arachis hypogaea extract - Article 28 - EMEA/H/C/004810

DBV Technologies; treatment of peanut allergy

Scope: Withdrawal of initial marketing authorisation application

Action: For information

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

CHMP noted the withdrawal of the initial marketing authorisation application.

3.7.2. Aliqopa - copanlisib - Orphan - EMEA/H/C/004334

Bayer AG; treatment of adult patients with relapsed marginal zone lymphoma

Scope: Withdrawal of initial marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 14.10.2021.

CHMP noted the withdrawal of the initial marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208/X/0004/G

Blueprint Medicines (Netherlands) B.V.

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add two new strengths of film-coated tablets (25 mg and 50 mg), grouped with a type II variation (C.I.6.a) to introduce a new therapeutic indication for Ayvakyt. Extension of indication to include treatment of adult patients with advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL), after at least one systemic therapy for Ayvakyt based on the results of the BLU-285-2101 and BLU-285-2202 studies. The new indication is applicable to the new and existing presentations (25 mg, 50 mg, 100 mg and 200 mg film-coated tablets). As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 5.3, 6.1 and 8 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. Version 1.1 of the RMP has also been submitted."

Action: For adoption

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the similarity assessment report.

4.1.2. Dupixent - dupilumab - EMEA/H/C/004390/X/0045/G

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola

Scope: "1- Extension of a marketing authorisation for Dupixent to add a new strength, 100 mg solution for injection.
2- Type II (C.I.6) - Extension of indication to include treatment of paediatric patients with severe asthma with type 2 inflammation aged 6 to 11 years old.
Version 6.0 of the RMP has also been submitted."

Action: For adoption

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on

22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Sogroya - somapacitan - Orphan - EMEA/H/C/005030/X/0001/G

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new strength of 5 mg/1.5 mL (3.3 mg/mL) grouped with a Type II Quality variation and a Type IA variation. RMP was updated (version 2.0) accordingly."

Action: For adoption

List of Questions adopted on 14.10.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to orphan similarity.

The Committee adopted a list of outstanding issues with a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Rinvoq - upadacitinib - EMEA/H/C/004760/X/0012/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension application to add a new strength (45 mg) of the prolonged-release tablets, grouped with a type II variation (C.I.6.a) to include the treatment of adults with moderately to severely active ulcerative colitis who had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent; as a consequence of the EoI, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 6.0) has also been submitted."

Action: For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to clinical aspects.

The Committee adopted a list of questions with a specific timetable.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Zejula - niraparib - Orphan - EMEA/H/C/004249/X/0029

GlaxoSmithKline (Ireland) Limited

Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension application to introduce a new pharmaceutical form (100 mg film-coated tablet). The RMP (version 5.1) is updated in accordance."

Request by the applicant dated 21 January 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in December 2021.

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 14.10.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in December 2021.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Briviact - brivaracetam - EMEA/H/C/003898/II/0032/G

UCB Pharma S.A.

Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski

Scope: "- Extension of indication to include patients from 2 years to 4 years of age for the treatment, as adjunctive therapy, of partial onset seizures with or without secondary generalisation. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The RMP version 8.1 has also been agreed.
- (B.II.f.1.b.2). As a consequence, section 6.3 of the SmPC (oral solution) is updated. Furthermore, the PI is brought in line with the latest QRD template version 10.2 and the MAH took the opportunity to implement minor editorial updates
The Package Leaflet and Labelling are updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021, 16.09.2021, 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

5.1.2. Cosentyx - secukinumab - EMEA/H/C/003729/II/0079

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "C.I.6 (Extension of indication) Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy for Cosentyx; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.3. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0012

Daiichi Sankyo Europe GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen for Enhertu based on final results from studies DS8201 A J202 (DESTINY Gastric01) and DS8201-A-U205 (DESTINY Gastric02); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.4. Hemlibra - emicizumab - EMEA/H/C/004406/II/0027

Roche Registration GmbH

Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of adult and paediatric patients with haemophilia A without factor VIII (FVIII) inhibitors who have mild or moderate disease for whom prophylaxis is clinically indicated. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC and section 1 of the package leaflet are updated. In addition, section 4.2 is updated to make it clear that the maintenance dose for Hemlibra applies from week 5 of dosing. The PIL is updated accordingly. Version 4.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.5. Imcivree - setmelanotide - Orphan - EMEA/H/C/005089/II/0002/G

Rhythm Pharmaceuticals Netherlands B.V.

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Marek Juracka

Scope: "Group of variations consisting of:
C.I.6.a - To add the new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC and sections 1, 3 and 4 of the PL are updated accordingly. The updated RMP version 1.0 has also been submitted.
C.I.6.a - To add the new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Alström syndrome (AS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC and sections 1, 3 and 4 of the PL are updated accordingly. The updated RMP version 1.0 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.6. Jardiance - empagliflozin - EMEA/H/C/002677/II/0060

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to add the treatment of symptomatic chronic heart failure based on the results from the clinical study 1245.110 EMPEROR-preserved.
As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC and sections 1, 2 and 4 of the PIL are updated accordingly. Further, the MAH applied for an additional year of market protection. The updated RMP v 16.0 has also been submitted.
In addition, the statement 'sodium free' was re-located from section 2 of the SmPC to section 4.4. to comply with EMA'S QRD guidance and minor linguistic changes to the national translations are included in this submission.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0117

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include a new indication for Keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults; as a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 38.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Lynparza - olaparib - EMEA/H/C/003726/II/0051/G

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include adjuvant treatment of breast cancer for Lynparza (for tablets); as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. In addition, section 4.8 of the SmPC for Lynparza hard capsules is revised based on the updated safety data analysis. The Package Leaflet is updated in accordance. Version 23 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0116

Novo Nordisk A/S

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of severe postpartum haemorrhage for NovoSeven. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is also updated in accordance. Version 8.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.10. Reblozyl - luspatercept - Orphan - EMEA/H/C/004444/II/0009

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Daniela Philadelphy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Laurence de Fays

Scope: "C.I.6 (Extension of indication)
Extension of indication in β-thalassaemia to include adult patients with non-transfusion dependent β-thalassaemia (NTDT) for Reblozyl; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.11. Senshio - ospemifene - EMEA/H/C/002780/II/0041

Shionogi B.V.

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication by lifting the second line treatment restriction. This is supported by the submission of the final study report of the imposed non-interventional post-authorisation safety study. As mentioned in Annex IID, this is an observational retrospective cohort study of ospemifene to assess the incidence of venous thromboembolism and other safety concerns as agreed in the Risk Management Plan (RMP), in vulvar and vaginal atrophy (VVA) patients treated with ospemifene compared to 1) patients newly prescribed SERMs for oestrogen-deficiency conditions or breast cancer prevention, and 2) the incidence in untreated VVA patients. As a consequence, section 4.1 of the SmPC is updated. The Package Leaflet and Annex IID are updated in accordance. Version 2 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to update the list of local representatives in the Package Leaflet. The variation leads to amendments to the Summary of Product Characteristics, Annex II D and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

5.1.12. Tecfidera - dimethyl fumarate - EMEA/H/C/002601/II/0073

Biogen Netherlands B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber

Scope: "C.I.6 (Extension of indication) type II Art.29 Extension of indication to include treatment of relapsing remitting multiple sclerosis (RRMS) in paediatrics patients from 13 years of age and over; as a consequence sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.3 and 6.6 of the Summary of Product Characteristics are updated. The Package Leaflet is updated accordingly. The risk management plan (RMP) is updated to version 13 based on study 109MS306 data supporting the request for a paediatric indication. The marketing authorisation holder took the opportunity to update the RMP with the most updated data (Part II modules SIV, SV and SVII)."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

5.1.13. Verzenios - abemaciclib - EMEA/H/C/004302/II/0013

Eli Lilly Nederland B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include Verzenios in combination with endocrine therapy for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021, 24.06.2021, 25.02.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 4th request for supplementary information with a specific timetable.

5.1.14. WS2049/G
Lacosamide UCB - lacosamide - EMEA/H/C/005243/WS2049/0009/G
Vimpat - lacosamide - EMEA/H/C/000863/WS2049/0091/G

UCB Pharma S.A.

Lead Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "- Extension of indication to include patients from 2 years to 4 years of age for treatment of partial-onset seizures with or without secondary generalisation as monotherapy and adjunctive therapy for Vimpat/Lacosamide USB. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. Version 16.2 of the RMP is also agreed.
- (B.II.f.1.b.2). As a consequence, section 6.3 of the SmPC (syrup) is updated.
Changes were also made to the PI to implement editorial updates and bring it in line with the latest QRD template.
The Package Leaflet and labelling are updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021, 16.09.2021, 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G

Teva B.V.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Letter from the applicant dated 20 December 2021 requesting an extension to the clock stop to respond to the request for supplementary information adopted in October 2021.

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021, 12.11.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the request for supplementary information adopted in October 2021.

5.2.2. Revestive - teduglutide - Orphan - EMEA/H/C/002345/II/0054/G

Shire Pharmaceuticals Ireland Limited

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include patients from 4 months corrected gestational aged 1 year and above. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 are updated. The Package leaflet is updated accordingly. Update of Annex II to amend the date of completion of the post-authorisation study. The MAH took the opportunity to also amend local representatives."

Letter from the applicant dated 14 January 2022 requesting an extension to the clock stop to respond to the request for supplementary information adopted in November 2021.

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the request for supplementary information adopted in November 2021.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics – initial consultation

No items

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the information.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 4 recommendations for eligibility to PRIME: 4 were denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Comirnaty - tozinameran - EMEA/H/C/005735/II/0102

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information 6 months post-dose 2 follow-up for adolescence 12 through 15 years of age based on updated interim results from study C4591001, listed as a specific obligation; this

is a Phase 1/2/3, placebo-controlled, observer-blind, interventional, dose-finding, study to evaluate the safety, tolerability, immunogenicity and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals.
In addition, the MAH took the opportunity to implement minor editorial changes in section 6.3 of the SmPC and section 5 of the PIL of Comirnaty 30 micrograms/dose dispersion for injection."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.2. Comirnaty - tozinameran - EMEA/H/C/005735/II/0093

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information after booster dose, based on interim results from study C4591031, this is a randomized, placebo-controlled, phase 3 booster efficacy study involving participants ≥ 16 years of age who completed the primary series of BNT162b2 30 µg in study C4591001. The Package Leaflet and Labelling are updated accordingly.
In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.3. Elzonris - tagraxofusp - EMEA/H/C/005031/II/0009

Stemline Therapeutics B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Submission of the final report from study 20255431 (CRL-263114) 'Characterization of fixed choroid plexus samples from primate study MPI-2231-007 by Immunohistochemistry with DT, CD123, IL-3 and IgG' (MEA002) listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions. The RMP version 2.0 has also been submitted."

Action: For discussion

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.4. Naglazyme - galsulfase - EMEA/H/C/000640/II/0086

BioMarin International Limited

Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "C.I.11.b variation to update the RMP to version 6.4 to remove gastrointestinal haemorrhage, hepatic impairment and thrombocytopenia from the list of important potential risks. This proposed update is supported by the submission of the final report from the MPS VI Clinical Surveillance Program (CSP) listed as a Specific Obligation (SOB002) in the Annex II of the Product Information for this MAA under exceptional circumstances. This observational CSP was undertaken to characterise the natural progression of MPS VI, to evaluate the long-term safety and efficacy data from Naglazyme treatment, to collect information on the effect of Naglazyme treatment on lactation, growth and development of infants of Naglazyme treated mothers and to evaluate the effects of Naglazyme treatment on children under 5 years of age."

Action: For adoption

Request for Supplementary Information adopted on 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

Since all specific obligations imposed on the Marketing Authorisation have been fulfilled and data for Naglazyme is now considered to be comprehensive, there are no remaining grounds for the Marketing Authorisation to remain under exceptional circumstances.

9.1.5. COVID-19 vaccines use during pregnancy

Comirnaty; Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst

COVID-19 Vaccine Janssen; Rapporteur: Christophe Focke, Co-Rapporteur: Sol Ruiz, PRAC Rapporteur: Ulla Wändel Liminga

Nuvaxovid; Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Brigitte Keller-Stanislawski

Spikevax; Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Hans Christian Siersted

Vaxzevria; Rapporteur: Sol Ruiz, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

Scope: The CHMP has discussed in its December 2021 meeting the COVID-19 vaccine use during pregnancy and lactation and agreed on the importance of reviewing the current label as soon as possible. In order to do that, the CHMP has decided to request to the MAH a review of all available evidence on vaccination in pregnant women and breastfeeding that has to be provided to the EMA as a LEG by 10 January 2022, at the latest.

The review should not be limited to data generated/owned by the company but needs to include relevant literature as well as a progress update and/or data coming from the RMP

measures related to this topic. The MAH should, within this review, critically discuss the need to update the product information.

Action: For adoption

The Committee agreed to update the information on use in pregnancy and breastfeeding in section 4.6 of the SmPC and section 2 of the PL for the two mRNA vaccines Comirnaty and Spikevax. In addition, the CHMP considered that the data currently available for Vaxzevria, COVID-19 Vaccine Janssen and Nuvaxovid do not warrant an update of section 4.6 of the SmPC at this point in time. The available data do not raise any safety concern for any of the vaccines. These recommendations are in line with the ones given by the PRAC. The MAHs were informed accordingly.

9.1.6. Imbruvica - ibrutinib - EMEA/H/C/003791/II/0069

Janssen-Cilag International NV

Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Update of the SmPC section 4.4 to include information on fatal and serious cardiac arrythmias and cardiac failure, relevant warnings and periodical monitoring of patients following a safety assessment for increased risk of sudden death/cardiac death with the use of ibrutinib. Section 2 of the PL has been updated accordingly. Typographical errors have been corrected throughout the PI. The revised RMP version 11 has been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.7. Bosulif - bosutinib - EMEA/H/C/002373/II/0050/G

Pfizer Europe MA EEIG

Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber

Scope: "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect results from the studies B1871039 (SOB) and B1871040 (category 3); study B1871039 is a Phase 4 Safety and Efficacy Study of Bosutinib in Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukaemia Previously Treated With One or More Tyrosine Kinase Inhibitors and study B1871040 is an Open-Label Bosutinib Treatment Extension Study for Subjects With Chronic Myeloid Leukaemia (CML) who Have Previously Participated in Bosutinib Studies B1871006 or B1871008. The Package Leaflet is updated accordingly. The MAH requests deletion of the SOB from annex II of the PI and requests consideration for a switch of the Conditional Marketing Authorisation to a full Marketing Authorisation. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives for Belgium, Luxemburg, Germany and Northern Island in the Package Leaflet. The MAH is also asking the deletion of the product from the additional monitoring list."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.8. Spikevax - COVID-19 mRNA vaccine - EMEA/H/C/005791/II/0042

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include information on heterologous boosting using a 50 ug dose of Spikevax to boost subjects that have previously completed a primary vaccination series with any authorised COVID-19 vaccine, based on data from the DMID study 21-0012, a Phase 1/2 heterologous SARS-CoV-2 vaccine dosing (mRNA-1273 booster) study of the various vaccines authorized in the US under Emergency Use Authorisation in participants ≥ 18 years old (NCT04889209). In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Lagevrio – molnupiravir – EMEA/H/A-5(3)/1512

Merck Sharp & Dohme B.V.; Treatment of coronavirus disease 2019 (COVID-19)

Scope: Revision of Opinion

Action: For adoption

Request for CHMP opinion under Article 5(3) of Regulation (EC) No 726/2004 on potential use of molnupiravir for the treatment of COVID-19 in adult patients

Opinion adopted on 19 November 2021.

The CHMP adopted the revised opinion.

10.2.2. Update on Q&A for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products (EMA/409815/2020 Rev.6)

CMDh question to SWP to determine the acceptable intake for N-Nitroso-folic acid based on lifetime daily exposure including information on the points of departure and methodology used.

Action: For adoption

The CHMP adopted the updated Q&A on nitrosamines.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Nasolam – midazolam - EMEA/H/A-29(4)/1511

Tiofarma B.V

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kristina Dunder

Scope: Opinion

Action: For adoption

Decentralised procedure number: NL/H/5089/001-003/DC, notification by the Agency of the Netherlands dated 24 September 2021 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

The CHMP adopted an opinion by majority (24 out of 32 votes) concluding that the marketing authorisation(s) should be granted. The CHMP adopted the assessment report.

The divergent position (Simona Badoi, Kristina Dunder, Ondrej Slanar, Blanka Hirschlerova, Elita Poplavska, Armando Genazzani, Alexandre Moreau and Agnes Gyurasics) was appended to the opinion.

The CHMP noted the EMA communication.

10.4.2. Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516

Zentiva k.s.

Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani

Scope: Start of procedure, list of questions, timetable, appointment of rapporteurs

Action: For adoption

Decentralised Procedure number: SE/H/2098/01–06/DC; SE/H/2099/01–06/DC, notification by the Swedish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MSs are of the opinion that a positive benefit risk balance is not established under Article 10(3) of Directive 2001/83/EC, as applied, in the absence of bioequivalence and that additional justification is needed to support extrapolation of efficacy and safety to the reference product. Concerns are also raised on the different warning with the reference medicinal product regarding concomitant administration of PPI and /or H2-antagonist and the risk of medication error.

The CHMP appointed Filip Josephson as Rapporteur and Armando Genazzani as Co-Rapporteur for the referral.

The CHMP adopted a list of questions with a specific timetable.

Notification: 23 December 2021

Start of procedure (CHMP): January 2022 CHMP

List of Questions: 27 January 2022

Submission of responses: 04 March 2022

Re-start of the procedure: 25 March 2022

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 30 March 2022

Comments: 05 April 2022

Updated rapporteur/co-rapporteur assessment reports circulated to CHMP: 11 April 2022

CHMP list of outstanding issues / CHMP opinion: April 2022 CHMP

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Stresam and generics – etifoxine (hydrochloride) - EMEA/H/A-31/1509

Biocodex

Referral Rapporteur: John Joseph Borg, Co-Rapporteur: Simona Badoi (collaboration with Bulgaria)

Scope: Opinion

Action: For adoption

ANSM has triggered a referral under Article 31 of Directive 2011/83/EC to review the B/R balance of etifoxine containing products, in light of the new results from the AMETIS study.

See 2.4

The CHMP agreed that an oral explanation was not needed at this time.

The CHMP adopted an opinion by majority (29 out of 30 votes) concluding that the marketing authorisations for Stresam and generics should be varied.

The divergent position (Alexandre Moreau) was appended to the opinion.

The CHMP noted the EMA communication.

10.6.2. Synchron Research Services – various – EMEA/H/A-31/1515

Various

Referral Rapporteur: Kristina Dunder, Referral Co-Rapporteur: Janet Koenig

Scope: Start of procedure, list of questions, timetable, appointment of rapporteurs

Action: For adoption

Article 31 procedure triggered by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, the Danish Medicines Agency (DKMA), the Finnish Medicines Agency (Fimea), the Medicines Evaluation Board (MEB) in the Netherlands and the Medical Products Agency (MPA) in Sweden concerning the contract research organisation (CRO) Synchron Research Services, located in Ahmedabad, Gujarat, India

The CHMP appointed Kristina Dunder as Rapporteur and Janet Koenig as Co-Rapporteur (Multinational team with DK, LT and SK) for the referral.

The CHMP adopted two lists of questions with a specific timetable.

Notifications: 11 January 2022

Start of the procedure (CHMP): January, 2022 CHMP

Lists of questions: 27 January 2022

Submission of responses: 04 March 2022

Re-start of the procedure: 25 March 2022

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 28 April 2022

Comments: 06 May 2022

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 12 May 2022

CHMP list of outstanding issues/CHMP opinion: May 2022 CHMP

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

10.7.1. Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506

International Drug Development France

Re-examination Referral Rapporteur: Ewa Balkowiec Iskra, Re-examination Co-Rapporteur: Janet Koenig

Initial assessment: Referral Rapporteur: Kristine Moll Harboe, Co-Rapporteur: Paula Boudewina van Hennik

Scope: Oral explanation/ Opinion

Action: For adoption

Decentralised Procedure number: DK/H/3106/001/DC, notification by the Danish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MS is of the opinion that therapeutic equivalence has not been demonstrated between the test and the reference product.

See 2.4

An oral explanation was held on Monday, 24 January 2022. The presentation by the applicant focused on the clinical data in support of the application.

The CHMP noted the withdrawal of the application procedure no. DK/H/3106/001/DC, Lidocaine/Prilocaine IDETEC.

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

January 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for January 2022

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at January 2022 PDCO

Action: For information

Report from the PDCO meeting held on 18-21 January 2022

Action: For information

The CHMP noted the information.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz

Reports from BWP January 2022 meeting to CHMP for adoption:

- 24 reports on products in scientific advice and protocol assistance
- 11 reports on products in pre-authorisation procedures
- 6 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 10-13 January 2022. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.3. CMDh request to SWP on the AI for the nitrosamines N-Nitroso-folic acid

Chair: Susanne Brendler-Schwaab

CMDh question to SWP to determine the acceptable intake for N-Nitroso-folic acid based on lifetime daily exposure including information on the points of departure and methodology used.

Action: For adoption

The CHMP endorsed the CMDh question to SWP.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the update.

15.1.2. Tixagevimab/Cilgavimab – EMEA/H/C/005837

treatment of COVID-19

Scope: Rolling review 1st interim opinion

Action: For information

The CHMP noted the closure of the 1st cycle of rolling review.

Lists of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 24-27 January 2022 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Thalia Marie Estrup Blicher	Alternate	Denmark	No participation in final deliberations and voting on	Sogroya - somapacitan - X/0001/G NovoSeven - eptacog alfa (activated) - II/0116
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jan Sjöberg	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID-19 vaccines
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Grzegorz Cessak	Alternate	Poland	No participation in final deliberations and voting on	COVID-19 vaccines
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No restrictions applicable to this meeting	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Catherine Deguines	Expert - via WebEx*	France	No interests declared	
Elsa Grangier	Expert - via WebEx*	France	No interests declared	
Claire-Li Ding	Expert - via WebEx*	France	No interests declared	
Naissant Gwladys	Expert - via WebEx*	France	No part in discussions, final deliberations and voting on	insulin aspart - EMEA/H/C/005635 Dupixent -

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
				dupilumab - X/0045/G
Roxane Fornacciari	Expert - via WebEx*	France	No interests declared	
Marika Doucet	Expert - via WebEx*	France	No interests declared	
Jana Klimasová	Expert - via WebEx*	Slovakia	No restrictions applicable to this meeting	
Peter Sisovsky	Expert - via WebEx*	Slovakia	No interests declared	
Eva Malikova	Expert - via WebEx*	Slovakia	No interests declared	
Anna Kubandová	Expert - via WebEx*	Slovakia	No interests declared	
Jana Schweigertova	Expert - via WebEx*	Slovakia	No interests declared	
Robert Nistico	Expert - via WebEx*	Malta	No interests declared	
Stephanie Liane Cini	Expert - via WebEx*	Malta	No interests declared	
Sara Camilleri	Expert - via WebEx*	Malta	No interests declared	
Karin Nylén	Expert - via WebEx*	Sweden	No interests declared	
Liisa Pylkkanen	Expert - via WebEx*	Finland	No interests declared	
Antero Kallio	Expert - via WebEx*	Finland	No restrictions applicable to this meeting	
Taina Methuen	Expert - via WebEx*	Finland	No interests declared	
Ieva Rutkovska	Expert - via WebEx*	Latvia	No interests declared	
Vita Gulevska	Expert - via WebEx*	Latvia	No interests declared	
Janis Kurlovics	Expert - via WebEx*	Latvia	No participation in discussion, final deliberations and voting on:	Nasolam – midazolam - EMEA/H/A-29(4)/1511
Kairi Rooma	Expert - via WebEx*	Estonia	No interests declared	
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No part in discussions, final deliberations and voting on:	Rinvoq - upadacitinib - X/0012/G
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Lucia Lopez-Anglada Fernandez	Expert - via WebEx*	Spain	No interests declared	
Alicia Pérez González	Expert - via WebEx*	Spain	No interests declared	
Ana Sagredo	Expert - via WebEx*	Spain	No interests declared	
Luisa Valer	Expert - via WebEx*	Spain	No interests declared	
Lourdes Rodriguez Rojas	Expert - via WebEx*	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Cristina Lucia Rueda Pérez	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Antonio Lopez Navas	Expert - via WebEx*	Spain	No interests declared	
Monica Beteta Robles	Expert - via WebEx*	Spain	No interests declared	
Eva Maria Nadal Elduayen	Expert - via WebEx*	Spain	No interests declared	
Paula Loekemeijer	Expert - via WebEx*	Netherlands	No interests declared	
Linda Trauffler	Expert - via WebEx*	Austria	No interests declared	
Sabrina Tripolt	Expert - via WebEx*	Austria	No interests declared	
Melanie Ramberger	Expert - via WebEx*	Austria	No interests declared	
Hannah Münch	Expert - via WebEx*	Austria	No interests declared	
Elisabeth Wischnitzki	Expert - via WebEx*	Austria	No interests declared	
Trine Jensen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Anne-Marie Dalseg	Expert - via WebEx*	Denmark	No interests declared	
Kristina Bech Jensen	Expert - via WebEx*	Denmark	No interests declared	
Aaron Emmanuel Sosa Mejia	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Nanna Borup Johansen	Expert - via WebEx*	Denmark	No interests declared	
Anne Hasle Buur	Expert - via WebEx*	Denmark	No interests declared	
Mette Linnert Jensen	Expert - via WebEx*	Denmark	No interests declared	
Mette Toftegaard Madsen	Expert - via WebEx*	Denmark	No interests declared	
Deirdre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Lene Weber Vestermark	Expert - via WebEx*	Denmark	No interests declared	
Andreas James Schaeffer Senders	Expert - via WebEx*	Denmark	No interests declared	
Doris Johanna Hovgaard	Expert - via WebEx*	Denmark	No interests declared	
Sine Buhl Naess-Schmidt	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Bibi Fatima Syed Shah	Expert - via WebEx*	Denmark	No interests declared	
Kristin Skougaard	Expert - via WebEx*	Denmark	No interests declared	
Claus Stage	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Loes den Otter	Expert - via WebEx*	Netherlands	No interests declared	
Lieke Sandberg Smits	Expert - via WebEx*	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Antonius Ederveen	Expert - via WebEx*	Netherlands	No interests declared	
Britt Duijndam	Expert - via WebEx*	Netherlands	No interests declared	
Valentina Lorenzi	Expert - via WebEx*	Netherlands	No interests declared	
Ate Duursma	Expert - via WebEx*	Netherlands	No interests declared	
Kommerie Hendrik	Expert - via WebEx*	Netherlands	No interests declared	
Margje Monster-Simons	Expert - via WebEx*	Netherlands	No interests declared	
Taco Monster	Expert - via WebEx*	Netherlands	No interests declared	
Andre Elferink	Expert - via WebEx*	Netherlands	No interests declared	
Rou-Afza Gunput	Expert - via WebEx*	Netherlands	No interests declared	
Jan Welink	Expert - via WebEx*	Netherlands	No interests declared	
Cristel Loeb	Expert - via WebEx*	Netherlands	No interests declared	
Adrianus Van Gompel	Expert - via WebEx*	Netherlands	No interests declared	
Laura Rodwell	Expert - via WebEx*	Netherlands	No interests declared	
Alida Spruijt	Expert - via WebEx*	Netherlands	No interests declared	
Hinke Johanna Van der Woude	Expert - via WebEx*	Netherlands	No interests declared	
Liesbeth Van Vlijmen	Expert - via WebEx*	Netherlands	No interests declared	
Nienke Rodenhuis	Expert - via WebEx*	Netherlands	No interests declared	
Illiana Meurs	Expert - via WebEx*	Netherlands	No interests declared	
Quirine Fillekes	Expert - via WebEx*	Netherlands	No interests declared	
Rutger de Vries	Expert - via WebEx*	Netherlands	No interests declared	
Esther Brandon	Expert - via WebEx*	Netherlands	No interests declared	
Ira Koval	Expert - via WebEx*	Netherlands	No restrictions applicable to this meeting	
Louise Claessen	Expert - via WebEx*	Netherlands	No interests declared	
Mette Tranholm	Expert - via WebEx*	Denmark	No interests declared	
Ulla Wändel Liminga	Expert - via WebEx*	Sweden	No interests declared	
Paolo Foggi	Expert - via WebEx*	Italy	No interests declared	
Adriana Ammassari	Expert - via WebEx*	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Luca Santi	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Cristina Migali	Expert - via WebEx*	Italy	No interests declared	
Maria Grazia Evandri	Expert - via WebEx*	Italy	No interests declared	
Michela Piezzo	Expert - via WebEx*	Italy	No interests declared	
Barbara Bonamassa	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Odoardo Maria Olimpieri	Expert - via WebEx*	Italy	No interests declared	
Antonella Isgrò	Expert - via WebEx*	Italy	No interests declared	
Angelo Molinaro	Expert - via WebEx*	Italy	No interests declared	
Sara Galluzzo	Expert - via WebEx*	Italy	No interests declared	
Sabine Mayrhofer	Expert - via WebEx*	Germany	No interests declared	
Irene Bachmann	Expert - via WebEx*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via WebEx*	Germany	No interests declared	
Anne Isabel Roth	Expert - via WebEx*	Germany	No interests declared	
George Aislaitner	Expert - via WebEx*	Germany	No interests declared	
Sylvia Kuehn	Expert - via WebEx*	Germany	No restrictions applicable to this meeting	
Sofia Kapanadze	Expert - via WebEx*	Germany	No restrictions applicable to this meeting	
Federico Marighetti	Expert - via WebEx*	Germany	No interests declared	
Hilke Zander	Expert - via WebEx*	Germany	No interests declared	
Rolf Gedeborg	Expert - via WebEx*	Sweden	No restrictions applicable to this meeting	
Kristin Elf	Expert - via WebEx*	Sweden	No restrictions applicable to this meeting	
Martin Huber	Expert - via WebEx*	Germany	No interests declared	
Olga Kholmanskikh	Expert - via WebEx*	Belgium	No interests declared	
Alexandru Mihail Simion	Expert - via WebEx*	Belgium	No interests declared	
Filip Van Nuffel	Expert - via WebEx*	Belgium	No interests declared	
Tim Leest	Expert - via WebEx*	Belgium	No interests declared	
Miranda Vroenhove	Expert - via WebEx*	Belgium	No interests declared	
Ingrid Bourges	Expert - via WebEx*	Belgium	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Valerie Lescrainier	Expert - via WebEx*	Belgium	No interests declared	
Geraldine O'Dea	Expert - via WebEx*	Ireland	No interests declared	
Catherine Byrne	Expert - via WebEx*	Ireland	No interests declared	
Benita Cullen	Expert - via WebEx*	Ireland	No interests declared	
Hans Christian Siersted	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Alessandro Assisi	Expert - via WebEx*	Italy	No interests declared	
Stefania Bellino	Expert - via WebEx*	Italy	No interests declared	
Giancarlo Zito	Expert - via WebEx*	Italy	No interests declared	
Greger Abrahamsen	Expert - via WebEx*	Norway	No interests declared	
Oyvind Holte	Expert - via WebEx*	Norway	No interests declared	
Venke Skibeli	Expert - via WebEx*	Norway	No interests declared	
Therese Solstad Saunders	Expert - via WebEx*	Norway	No interests declared	
Petra Ekerot	Expert - via WebEx*	Sweden	No restrictions applicable to this meeting	
Anja Schiel	Expert - via WebEx*	Norway	No interests declared	
Pierre Demolis	Expert - via WebEx*	France	No interests declared	
Serena Marchetti	Expert - via WebEx*	Netherlands	No interests declared	
Mirjam Hinterleitner	Expert - via WebEx*	Austria	No interests declared	
Tjerk Feenstra	Expert - via WebEx*	Austria	No interests declared	
Florian Stampfer	Expert - via WebEx*	Austria	No interests declared	
Bernice Aronsson	Expert - via WebEx*	Sweden	No interests declared	
Helena Back	Expert - via WebEx*	Sweden	No interests declared	
Ana Claudia Figueiredo	Expert - via WebEx*	Portugal	No interests declared	
Paulo Paixão	Expert - via WebEx*	Portugal	No interests declared	
Joao Rocha	Expert - via WebEx*	Portugal	No interests declared	
Mario Miguel Coelho da Silva Rosa	Expert - via WebEx*	Portugal	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Inne Crèvecoeur	Expert - via WebEx*	Belgium	No participation in discussion, final deliberations and voting on:	gefapixant - EMEA/H/C/005884 gefapixant - EMEA/H/C/005476 Keytruda - pembrolizumab - EMEA/H/C/003820/II/0117
Violette Dirix	Expert - via WebEx*	Belgium	No interests declared	
Edwige Haelterman Brenneisen	Expert - via WebEx*	Belgium	No interests declared	
Bruno Delafont	Expert - via WebEx*	France	No participation in discussion, final deliberations and voting on:	Lynparza - olaparib - EMEA/H/C/003726/II/0051/G Tixagevimab/ Cilgavimab – EMEA/H/C/005837
Fabien Lavergne	Expert - via WebEx*	France	No interests declared	
Mona Kassem-Youssef	Expert - via WebEx*	France	No interests declared	
Nathalie Morgensztejn	Expert - via WebEx*	France	No interests declared	
Nicolas Beix	Expert - via WebEx*	France	No interests declared	
Vincent Gazin	Expert - via WebEx*	France	No interests declared	
Helena Faust	Expert - via WebEx*	Sweden	No interests declared	
Anette Kirstine Stark	Expert - via WebEx*	Denmark	No interests declared	
Andrea Logreco	Expert - via WebEx*	Italy	No interests declared	
Camilla Festa	Expert - via WebEx*	Italy	No interests declared	
Jeanette McCallion	Expert - via WebEx*	Ireland	No interests declared	
Larissa Higgins	Expert - via WebEx*	Ireland	No interests declared	
Andrea Röhmer	Expert - via WebEx*	Germany	No interests declared	
Leonor Wijnans	Expert - via WebEx*	Netherlands	No interests declared	
Alessia Proietti	Expert - via WebEx*	Italy	No interests declared	
Jean-Michel Dogné	Expert - via WebEx*	France	No interests declared	
Menno van der Elst	Expert - via WebEx*	Netherlands	No interests declared	
Lothar Bergmann	Expert - via Telephone	Germany	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Megan Hickie	Expert - via WebEx*	TGA Australia	No interests declared	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

11 March 2022
EMA/CHMP/52295/2022

Annex to 24-27 January 2022 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for January 2022: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for January 2022: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Myalepta - metreleptin - EMEA/H/C/004218/S/0023, Orphan Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted on 27.01.2022.	Request for supplementary information adopted with a specific timetable.
Raxone - idebenone - EMEA/H/C/003834/S/0029, Orphan Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli Request for Supplementary Information adopted on 27.01.2022.	Request for supplementary information adopted with a specific timetable.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

Brineura - cerliponase alfa - EMEA/H/C/004065/R/0034, Orphan BioMarin International Limited, Rapporteur: Martina Weise, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. Based on the review of the available information, the CHMP was of the opinion that an additional five-year renewal was required.

Request for Supplementary Information adopted on 11.11.2021.	

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Dupixent - dupilumab - EMEA/H/C/004390/R/0053 sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola Request for Supplementary Information adopted on 27.01.2022.	Request for supplementary information adopted with a specific timetable.
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004250/R/0025 Zentiva k.s., Generic, Generic of Atripla (SRD), Rapporteur: Tomas Radimersky, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 27.01.2022.	Request for supplementary information adopted with a specific timetable.
Erelzi - etanercept - EMEA/H/C/004192/R/0037 Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Insulin lispro Sanofi - insulin lispro - EMEA/H/C/004303/R/0013 sanofi-aventis groupe, Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Annika Folin	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Kisqali - ribociclib - EMEA/H/C/004213/R/0034 Novartis Europharm Limited, Rapporteur: Filip Josephson, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Anette Kirstine Stark	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Kyntheum - brodalumab - EMEA/H/C/003959/R/0019 LEO Pharma A/S, Rapporteur: Johann Lodewijk	Request for supplementary information adopted with a specific timetable.

Hillege, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Eva A. Segovia Request for Supplementary Information adopted on 27.01.2022.	
Maviret - glecaprevir / pibrentasvir - EMEA/H/C/004430/R/0048 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Jean-Michel Race, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
OXERVATE - cenegermin - EMEA/H/C/004209/R/0037, Orphan Dompe farmaceutici S.p.A., Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Reagila - cariprazine - EMEA/H/C/002770/R/0026 Gedeon Richter Plc., Rapporteur: Kristina Dunder, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
TAGRISSO - osimertinib - EMEA/H/C/004124/R/0044 AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Trimbow - beclometasone / formoterol / glycopyrronium bromide - EMEA/H/C/004257/R/0025 Chiesi Farmaceutici S.p.A., Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Ucedane - carglumic acid - EMEA/H/C/004019/R/0011 Eurocept International B.V., Generic, Generic of Carbaglu, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that

	the renewal of the marketing authorisation can be granted with unlimited validity.
Veltassa - patiromer - EMEA/H/C/004180/R/0028 Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Kirsti Villikka Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

B.2.3. Renewals of Conditional Marketing Authorisations

Bosulif - bosutinib - EMEA/H/C/002373/R/0051 Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. See also 9.1
Deltyba - delamanid - EMEA/H/C/002552/R/0052, Orphan Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Laurence de Fays Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Lorviqua - lorlatinib - EMEA/H/C/004646/R/0019 Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Nikica Mirošević Skvrce	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Natpar - parathyroid hormone - EMEA/H/C/003861/R/0034, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Rhea Fitzgerald Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Ondexxya - andexanet alfa -	Positive Opinion adopted by consensus together

EMEA/H/C/004108/R/0025 Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst	with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Pandemic influenza vaccine H5N1 AstraZeneca - pandemic influenza vaccine (h5n1) (live attenuated, nasal) - EMEA/H/C/003963/R/0047 AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Rubraca - rucaparib - EMEA/H/C/004272/R/0030 Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection PRAC recommendations on signals adopted at the PRAC meeting held on 10-13 January 2022 PRAC:	
Signal of arthralgia Imfinzi – durvalumab Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen PRAC recommendation on a variation **Action:** For adoption	Adopted
Signal of toxic epidermal necrolysis Lyrica – pregabalin Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan PRAC recommendation on a variation **Action:** For adoption	Adopted
PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its January 2022 meeting:	

EMEA/H/C/PSUSA/00000274/202105 (azacitidine) CAPS: **Vidaza** (EMEA/H/C/000978) (azacitidine), Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "18/05/2018 To: 18/05/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction 'differentiation syndrome' with a frequency "not known". The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00000935/202106 (dasatinib) CAPS: **Sprycel** (EMEA/H/C/000709) (dasatinib), Bristol-Myers Squibb Pharma EEIG, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, "27/06/2020 To: 27/06/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add a warning on and to include the adverse reaction for chylothorax with a frequency Uncommon. The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00001725/202105 (imatinib) CAPS: **Glivec** (EMEA/H/C/000406) (imatinib), Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa NAPS: **NAP** - EU PRAC Rapporteur: Eva A. Segovia, "11/05/2018 To: 10/05/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.8 of the SmPC to add panniculitis (including erythema nodosum) with frequency Uncommon. The Package leaflet is updated accordingly.

EMEA/H/C/PSUSA/00002700/202105 (sildenafil (indicated for pulmonary hypertension)) CAPS: **Revatio** (EMEA/H/C/000638) (sildenafil), Upjohn EESV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, "01/06/2018 To: 31/05/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.5 of the SmPC to add a warning about the increase in hypotension observed with concomitant use of sildenafil and Entresto (sacubitril/valsartan). The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010516/202106 (opicapone) CAPS: **Ongentys** (EMEA/H/C/002790) (opicapone), Bial - Portela & Cª, S.A., Rapporteur: Martina Weise, PRAC Rapporteur: Maria del Pilar Rayon, "25/06/2020 To: 24/06/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change: Update of section 4.8 of the SmPC to add nausea with a frequency common (according to the frequency of clinical trials). The Package leaflet is updated accordingly. Update of section 4.4 of the SmPC to add sodium content as excipient in line with the QRD template. The PL is updated accordingly.
EMEA/H/C/PSUSA/00010761/202105 (pegvaliase) CAPS: **Palynziq** (EMEA/H/C/004744) (pegvaliase), BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald, "24/11/2020 To: 23/05/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add 'dizziness' to the list of hypersensitivity reaction terms included in the relevant footnote below the tabulated summary of ADRs. The Package leaflet is updated accordingly.

EMEA/H/C/PSUSA/00010787/202106 (ravulizumab) CAPS: **Ultomiris** (EMEA/H/C/004954) (ravulizumab), Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, "30/12/2020 To: 30/06/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction Urticaria with a frequency Uncommon. The Package leaflet is updated accordingly. Additionally, the MAH took the opportunity to include a minor edit in the footnote of the ADR table in section 4.8 of the SmPC.
EMEA/H/C/PSUSA/00010897/202106 (COVID-19 mRNA vaccine (nucleoside-modified) (Spikevax)) CAPS: **Spikevax** (EMEA/H/C/005791) (COVID-19 mRNA vaccine (nucleoside-modified)), Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted, "18/12/2020 To: 30/06/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above-mentioned medicinal product, concerning the following change: Update of section 4.8 of the SmPC to add the adverse reaction paraesthesia with a frequency 'rare' based on data assessed within this procedure. The package leaflet is updated accordingly.

B.4. EPARs / WPARs

ABYLQIS (WD) - arachis hypogaea extract - EMEA/H/C/004810, Article 28 DBV Technologies, treatment of peanut allergy, Known active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Aliqopa - copanlisib - EMEA/H/C/004334, Orphan Bayer AG, treatment of adult patients with relapsed marginal zone lymphoma, New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451	For information only. Comments can be sent to the PL in case necessary.

Pfizer Europe MA EEIG, prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, New active substance (Article 8(3) of Directive No 2001/83/EC)	
Kerendia - finerenone - EMEA/H/C/005200 Bayer AG, delay progression of kidney disease, reduce the risk of cardiovascular mortality and morbidity, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
NGENLA - somatrogon - EMEA/H/C/005633, Orphan Pfizer Europe MA EEIG, indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone., New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Okedi - risperidone - EMEA/H/C/005406 Laboratorios Farmacéuticos Rovi, S.A., treatment of schizophrenia, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Ontilyv - opicapone - EMEA/H/C/005782 Bial Portela & Companhia S.A., treatment of Parkinson's disease and motor fluctuations, Informed Consent of Ongentys, Informed consent application (Article 10c of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Oxbryta - voxelotor - EMEA/H/C/004869, Orphan Global Blood Therapeutics Netherlands, Indicated for the treatment of haemolytic anaemia in adults and paediatric patients 12 years of age and older with sickle cell disease (SCD)., New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Saphnelo - anifrolumab - EMEA/H/C/004975 AstraZeneca AB, indicated as an add-on therapy for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), despite standard therapy, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Sapropterin Dipharma - sapropterin - EMEA/H/C/005646	For information only. Comments can be sent to

Dipharma B.V., treatment of hyperphenylalaninemia (HPA), Generic, Generic of Kuvan, Generic application (Article 10(1) of Directive No 2001/83/EC)	the PL in case necessary.
Sitagliptin Metformin hydrochloride Mylan - metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678 Mylan Ireland Limited, treatment of type 2 diabetes mellitus, Generic, Generic of Janumet, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Sitagliptin SUN - sitagliptin fumarate - EMEA/H/C/005741 Sun Pharmaceutical, treatment of type 2 diabetes mellitus, Generic, Generic of Janumet, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
TEPMETKO - tepotinib - EMEA/H/C/005524 Merck Europe B.V., treatment of advanced non-small cell lung cancer. Treatment of adult patients with advanced non-small cell lung cancer, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Xevudy - sotrovimab - EMEA/H/C/005676 GlaxoSmithKline Trading Services Limited, Treatment of coronavirus disease 2019 (COVID-19), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Abevmy - bevacizumab - EMEA/H/C/005327/II/0005/G Mylan IRE Healthcare Limited, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 13.01.2022.
ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0027 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop	Positive Opinion adopted by consensus on 13.01.2022.

Opinion adopted on 13.01.2022.	
Alymsys - bevacizumab - EMEA/H/C/005286/II/0005 Mabxience Research SL, Rapporteur: Christian Gartner Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0157/G Amgen Europe B.V., Rapporteur: Martina Weise Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0158 Amgen Europe B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Bimzelx - bimekizumab - EMEA/H/C/005316/II/0003/G UCB Pharma S.A., Rapporteur: Peter Kiely Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Bimzelx - bimekizumab - EMEA/H/C/005316/II/0004 UCB Pharma S.A., Rapporteur: Peter Kiely Request for Supplementary Information adopted on 20.01.2022.	Request for supplementary information adopted with a specific timetable.
Cerezyme - imiglucerase - EMEA/H/C/000157/II/0123/G Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 13.01.2022, 14.10.2021.	Request for supplementary information adopted with a specific timetable.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0075/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 13.01.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0090 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 27.01.2022.	Positive Opinion adopted by consensus on 27.01.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0097 BioNTech Manufacturing GmbH, Rapporteur:	Positive Opinion adopted by consensus on 21.12.2021.

Filip Josephson Opinion adopted on 21.12.2021.	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0101 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 21.01.2022.	Positive Opinion adopted by consensus on 21.01.2022.
Darzalex - daratumumab - EMEA/H/C/004077/II/0056/G, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac Opinion adopted on 20.01.2022.	Positive Opinion adopted by consensus on 20.01.2022.
Dupixent - dupilumab - EMEA/H/C/004390/II/0050/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 14.10.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0009 Daiichi Sankyo Europe GmbH, Rapporteur: Sinan B. Sarac Opinion adopted on 20.01.2022. Request for Supplementary Information adopted on 28.10.2021.	Positive Opinion adopted by consensus on 20.01.2022.
Erbitux - cetuximab - EMEA/H/C/000558/II/0092 Merck Europe B.V., Rapporteur: Filip Josephson Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Erelzi - etanercept - EMEA/H/C/004192/II/0038/G Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 02.12.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Fasenra - benralizumab - EMEA/H/C/004433/II/0038/G AstraZeneca AB, Rapporteur: Fátima Ventura Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Febuxostat Mylan - febuxostat - EMEA/H/C/004374/II/0012	Request for supplementary information adopted with a specific timetable.

Mylan Pharmaceuticals Limited, Generic, Generic of Adenuric, Rapporteur: Elita Poplavska Request for Supplementary Information adopted on 27.01.2022.	
Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0021 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Hepcludex - bulevirtide - EMEA/H/C/004854/II/0009/G, Orphan Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson Opinion adopted on 27.01.2022.	Positive Opinion adopted by consensus on 27.01.2022.
Hepsera - adefovir dipivoxil - EMEA/H/C/000485/II/0087 Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
ILARIS - canakinumab - EMEA/H/C/001109/II/0078 Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Infanrix hexa - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/000296/II/0309/G GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Insulin lispro Sanofi - insulin lispro - EMEA/H/C/004303/II/0014/G sanofi-aventis groupe, Rapporteur: Outi Mäki-Ikola Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0061/G Roche Registration GmbH, Rapporteur: Sinan B. Sarac Opinion adopted on 27.01.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 27.01.2022.

on 09.12.2021.	
Kirsty - insulin aspart - EMEA/H/C/004965/II/0003/G Mylan IRE Healthcare Limited, Rapporteur: Sinan B. Sarac Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 09.12.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Leqvio - inclisiran - EMEA/H/C/005333/II/0008 Novartis Europharm Limited, Rapporteur: Martina Weise Request for Supplementary Information adopted on 27.01.2022.	Request for supplementary information adopted with a specific timetable.
Lysodren - mitotane - EMEA/H/C/000521/II/0024 HRA Pharma Rare Diseases, Rapporteur: Blanca Garcia-Ochoa Request for Supplementary Information adopted on 13.01.2022, 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Memantine Mylan - memantine / memantine hydrochloride - EMEA/H/C/002660/II/0018 Mylan Pharmaceuticals Limited, Generic, Generic of Ebixa, Rapporteur: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 20.01.2022.	Request for supplementary information adopted with a specific timetable.
Menveo - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/001095/II/0106/G GSK Vaccines S.r.l, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Mosquirix - plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0059/G GlaxoSmithkline Biologicals SA, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0023/G, Orphan Pfizer Europe MA EEIG, Rapporteur: Sinan B.	Request for supplementary information adopted with a specific timetable.

Sarac Request for Supplementary Information adopted on 27.01.2022.	
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0035, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Nordimet - methotrexate - EMEA/H/C/003983/II/0021/G Nordic Group B.V., Rapporteur: Bruno Sepodes Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Nplate - romiplostim - EMEA/H/C/000942/II/0081/G Amgen Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Olanzapine Apotex - olanzapine - EMEA/H/C/001178/II/0045 Apotex Europe BV, Generic, Generic of Zyprexa, Rapporteur: John Joseph Borg Request for Supplementary Information adopted on 13.01.2022, 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Onivyde pegylated liposomal - irinotecan hydrochloride trihydrate - EMEA/H/C/004125/II/0029/G, Orphan Les Laboratoires Servier, Rapporteur: Filip Josephson Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Oyavas - bevacizumab - EMEA/H/C/005556/II/0004 STADA Arzneimittel AG, Duplicate, Duplicate of Alymsys, Rapporteur: Christian Gartner Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Polivy - polatuzumab vedotin - EMEA/H/C/004870/II/0013/G, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau Opinion adopted on 27.01.2022.	Positive Opinion adopted by consensus on 27.01.2022.
POTELIGEO - mogamulizumab - EMEA/H/C/004232/II/0013/G, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 13.01.2022.	
ProQuad - measles, mumps, rubella and varicella vaccine (live) - EMEA/H/C/000622/II/0154 MSD Vaccins, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.01.2022. Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus on 20.01.2022.
Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0035/G, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 27.01.2022.	Positive Opinion adopted by consensus on 27.01.2022.
Rekovelle - follitropin delta - EMEA/H/C/003994/II/0030 Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Retacrit - epoetin zeta - EMEA/H/C/000872/II/0108 Pfizer Europe MA EEIG, Rapporteur: Martina Weise Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Rhokiinsa - netarsudil - EMEA/H/C/004583/II/0007/G Aerie Pharmaceuticals Ireland Limited, Rapporteur: Jayne Crowe Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 13.01.2022.
RoActemra - tocilizumab - EMEA/H/C/000955/II/0106/G Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Rybelsus - semaglutide - EMEA/H/C/004953/II/0020 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 27.01.2022.	Positive Opinion adopted by consensus on 27.01.2022.
Tigecycline Accord - tigecycline - EMEA/H/C/005114/II/0002/G Accord Healthcare S.L.U., Generic, Generic of Tygacil, Rapporteur: Daniela Philadelphy	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 13.01.2022.	
Toviaz - fesoterodine - EMEA/H/C/000723/II/0065/G Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 20.01.2022.	Request for supplementary information adopted with a specific timetable.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0061/G AstraZeneca AB, Co-Rapporteur: Johann Lodewijk Hillege Opinion adopted on 20.01.2022.	Positive Opinion adopted by consensus on 20.01.2022.
Xolair - omalizumab - EMEA/H/C/000606/II/0114 Novartis Europharm Limited, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Yuflyma - adalimumab - EMEA/H/C/005188/II/0009/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Opinion adopted on 20.01.2022. Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus on 20.01.2022.
Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0027/G Pfizer Ireland Pharmaceuticals, Rapporteur: Ingrid Wang Request for Supplementary Information adopted on 13.01.2022, 02.12.2021, 28.10.2021, 09.09.2021.	Request for supplementary information adopted with a specific timetable.
Zercepac - trastuzumab - EMEA/H/C/005209/II/0015/G Accord Healthcare S.L.U., Rapporteur: Sol Ruiz Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Zercepac - trastuzumab - EMEA/H/C/005209/II/0016 Accord Healthcare S.L.U., Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Zutectra - human hepatitis B immunoglobulin - EMEA/H/C/001089/II/0051	Positive Opinion adopted by consensus on 13.01.2022.

Biotest Pharma GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.01.2022.	
WS2164/G **Blitzima-EMEA/H/C/004723/WS2164/0047/G** **Truxima-EMEA/H/C/004112/WS2164/0051/G** Celltrion Healthcare Hungary Kft., Duplicate, Duplicate of Truxima, Lead Rapporteur: Sol Ruiz Opinion adopted on 20.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 20.01.2022.
WS2177/G **Nilemdo-EMEA/H/C/004958/WS2177/0018/G** **Nustendi-EMEA/H/C/004959/WS2177/0020/G** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2188/G **Hexacima-EMEA/H/C/002702/WS2188/0124/G** **Hexyon-EMEA/H/C/002796/WS2188/0128/G** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2189 **Advate-EMEA/H/C/000520/WS2189/0113** **ADYNOVI-EMEA/H/C/004195/WS2189/0026** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0028 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, "Update of section 4.8 of the SmPC in order to add ''Urticaria'' to the list of adverse drug reactions (ADRs) with frequency ''common''. The Package Leaflet is updated	Positive Opinion adopted by consensus on 13.01.2022.

accordingly." Opinion adopted on 13.01.2022.	
Alunbrig - brigatinib / brigatinib - EMEA/H/C/004248/II/0033/G Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information about the effect of brigatinib on the pharmacokinetics of a sensitive cytochrome P450 3A substrate (midazolam) in patients with ALK-positive or ROS1-positive solid tumours based on a clinical study report (study 1001). Update of sections 4.4 and 4.5 of the SmPC in order to update drug-drug interaction information regarding concomitant treatment with moderate CYP3A inducers based on results of previously submitted studies (physiologically-based pharmacokinetic (PBPK) report and PBPK report addendum). Update of section 5.1 of the SmPC in order to amend the ATC code. In addition, the MAH took the opportunity to implement a statement regarding the sodium content of Alunbrig in section 4.4 of the SmPC and Package Leaflet. The MAH also took the opportunity to bring the Product Information in line with the latest QRD template (version 10.2 rev.1) and to update the list of local representatives in the Package Leaflet. Moreover, the MAH took the opportunity to introduce minor editorial changes in the PI in different languages." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 14.10.2021, 22.07.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Alunbrig - brigatinib / brigatinib - EMEA/H/C/004248/II/0034 Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on photosensitivity based on a report of cumulative evidence for an association between exposure to brigatinib and subsequent development of photosensitivity reaction; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make a minor editorial change in section 4.8 of the SmPC." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 14.10.2021, 22.07.2021.	Positive Opinion adopted by consensus on 13.01.2022.

Blenrep - belantamab mafodotin - EMEA/H/C/004935/II/0006/G, Orphan GlaxoSmithKline (Ireland) Limited, Rapporteur: Johanna Lähteenvuo, "C.I.4 Update of section 4.4 of the SmPC in order to add a new warning on pneumonitis based on reports from the GSK safety database and clinical trials. C.I.4 Update of section 4.8 of the SmPC in order to add albuminuria to the list of adverse drug reactions (ADRs) with frequency common based on a safety review by the MAH. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to perform minor editorial changes." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0093 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information after booster dose, based on interim results from study C4591031, this is a randomized, placebo-controlled, phase 3 booster efficacy study involving participants ≥ 16 years of age who completed the primary series of BNT162b2 30 µg in study C4591001. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information." Request for Supplementary Information adopted on 27.01.2022	Request for supplementary information adopted with a specific timetable. See 9.1
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0102 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information 6 months post-dose 2 follow-up for adolescence 12 through 15 years of age based on updated interim results from study C4591001, listed as a specific obligation; this is a Phase 1/2/3, placebo-controlled, observer-blind, interventional, dose-finding, study to evaluate the safety, tolerability, immunogenicity and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. In addition, the MAH took the opportunity to	Positive Opinion adopted by consensus on 27.01.2022. See 9.1

implement minor editorial changes in section 6.3 of the SmPC and section 5 of the PIL of Comirnaty 30 micrograms/dose dispersion for injection." Opinion adopted on 27.01.2022.	
Copiktra - duvelisib - EMEA/H/C/005381/II/0002 Secura Bio Limited, Rapporteur: Sinan B. Sarac, "Update of section 5.1 of the SmPC based on the final overall survival results from study IPI-145-07, an interventinal Phase 3 Study of duvelisib (IPI-145) vs ofatumumab in patients with relapsed or refractory Chronic Lymphocytic leukaemia/Small Lymphocytic Lymphoma." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0014/G International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, "C.I.13: Submission of the study report from study MTN-020 (Version 2.0). This is a multicentre, randomized, double-blind, placebo-controlled Phase III safety and effectiveness trial of a vaginal matrix ring containing dapivirine for the prevention of HIV-1 infection in women. C.I.13: Submission of the Clinical Virology Report (Version 4.0). This report describes virologic characterisation of virus from HIV-1 seroconversion events during double-blind, placebo-controlled, randomized, multicentre Phase III clinical trials evaluating the safety and efficacy of Dapivirine Vaginal Ring." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Dovprela - pretomanid - EMEA/H/C/005167/II/0008, Orphan Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson, "Submission of the final report from study Nix-TB-(B-L-Pa) listed as a Specific Obligation the Annex II of the Product Information. This is a phase 3 open-label trial assessing the safety and efficacy of bedaquiline plus pretomanid plus linezolid in subjects with pulmonary infection of either extensively drug-resistant tuberculosis (XDR-TB) or treatment intolerant/non-responsive multi-drug resistant	Positive Opinion adopted by consensus on 13.01.2022.

tuberculosis (MDR-TB). The Annex II is updated accordingly." Opinion adopted on 13.01.2022.	
Epidyolex - cannabidiol - EMEA/H/C/004675/II/0015, Orphan GW Pharma (International) B.V., Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.5 and 5.1 of the SmPC to add drug-drug interaction information with everolimus and P-gp substrates following the assessment the study GWCP19195, a phase I open-label pharmacokinetic drug-drug interaction trial to investigate the effect of cannabidiol on the pharmacokinetics of everolimus in healthy subject. In addition, the MAH took the opportunity to introduce editorial updates in section 5.1 and section 4.9." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Epidyolex - cannabidiol - EMEA/H/C/004675/II/0016, Orphan GW Pharma (International) B.V., Rapporteur: Thalia Marie Estrup Blicher, "Update of section 5.3 of the SmPC to reflect of the conclusions of the study GWTX1504, 104 week oral (gavage) administration carcinogenicity study in mouse." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Eylea - aflibercept - EMEA/H/C/002392/II/0076 Bayer AG, Rapporteur: Alexandre Moreau, "Submission of the final report from study AZURE, a randomised PAES in patients with neovascular (wet) AMD with the primary objective of comparing the standard regime of injections every 8 weeks with a reactive regimen based on visual and anatomic outcomes, based on a CHMP approved protocol." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Fasenra - benralizumab - EMEA/H/C/004433/II/0041 AstraZeneca AB, Rapporteur: Fátima Ventura, "Update of section 5.1 of the SmPC in order to update efficacy information based on the final	Request for supplementary information adopted with a specific timetable.

results from study D3250C00065 (PONENTE); this is a multicenter, open-label, Phase IIIb efficacy and safety study of benralizumab 30 mg administered subcutaneously to reduce oral corticosteroid use in adult patients with severe eosinophilic asthma on high-dose inhaled corticosteroid plus long-acting β2 agonist and chronic oral corticosteroid therapy. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 27.01.2022.	
Fetcroja - cefiderocol - EMEA/H/C/004829/II/0006/G Shionogi B.V., Rapporteur: Filip Josephson, "Submission of the final report from the in vitro RIS correlation study S-649266-PF-415-N (REC 003), to address CYP3A4 induction by cefiderocol. In addition, the MAH submitted the final report of in vitro study S-649266-CPK-008-C to investigate the DDI between cefiderocol as a CYP3A4 inducer and Midazolam using physiologically-based pharmacokinetic model." Request for Supplementary Information adopted on 13.01.2022, 11.11.2021.	Request for supplementary information adopted with a specific timetable.
Iclusig - ponatinib - EMEA/H/C/002695/II/0061, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on results from the OPTIC study (AP24534-14-203) listed as a specific obligation in the Annex II. This is a randomised, open-label, Phase 2 trial of ponatinib in patients with chronic myeloid leukaemia to characterise the efficacy and safety of ponatibib over a range of doses; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 13.01.2022, 14.10.2021.	Request for supplementary information adopted with a specific timetable.
IMCIVREE - setmelanotide - EMEA/H/C/005089/II/0003, Orphan Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn, "Update of sections 4.2 and 5.2 of the SmPC in order to change posology recommendations in patients with renal impairment, based on final results from study RM-493-029, a Phase I, open-label, single-dose study to evaluate the	Request for supplementary information adopted with a specific timetable.

pharmacokinetics of setmelanotide in subjects with varying degrees of renal impairment; with secondary objectives to evaluate the safety and tolerability of a single dose of setmelanotide administered subcutaneously in subjects with varying degrees of renal impairment. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 27.01.2022.	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0034 AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Update of sections 4.4 and 4.8 of the SmPC in order to reflect the outcome of the re-defined process to identify and calculate immune-mediated Adverse Event (imAE) rates from clinical study and pooled datasets within the durvalumab development programmes. In addition, the MAH implemented minor editorial corrections to sections 4.4 and 5.1 of the SmPC." Request for Supplementary Information adopted on 20.01.2022, 21.10.2021.	Request for supplementary information adopted with a specific timetable.
JEMPERLI - dostarlimab - EMEA/H/C/005204/II/0007 GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update dose modifications recommendations in immune related adverse reactions, amend existing warnings, and add further immune-related ADRs to the list of adverse drug reactions (ADRs), with different frequencies, based on data from company sponsored trials and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to remove information on Polysorbate 80 and update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 27.01.2022.	Request for supplementary information adopted with a specific timetable.
Jyseleca - filgotinib - EMEA/H/C/005113/II/0008 Galapagos N.V., Rapporteur: Kristina Dunder, "C.I.4 - Update of section 4.8 of the SmPC in order to add Lymphopenia to the list of adverse drug reactions (ADRs) with frequency common and update the information on serum phosphate and the experience from the long-term	Request for supplementary information adopted with a specific timetable.

extension studies based on interim results from study GS-US-417-0304 (FINCH 4); this is a Multicenter, Double-Blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 13.01.2022, 09.09.2021.	
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0087 Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of section 4.8 of the SmPC in order to add palpitations, asthenia, malaise, feeling cold and blood pressure decreased to the list of adverse drug reactions (ADRs) with frequency "not-known" following the Final Assessment Report for the Post-Authorisation Measure MEAs 024.13 and 0.25.13 (the 2019 Pompe Disease Registry Annual Report) dated 15 October 2020; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 5.1 of the SmPC to update the internet website address of the Pompe Registry." Request for Supplementary Information adopted on 20.01.2022.	Request for supplementary information adopted with a specific timetable.
Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0050 Orexigen Therapeutics Ireland Limited, Rapporteur: Sinan B. Sarac, "Submission of the final report of study 20077697; a Toxicity Study of Bupropion and Naltrexone by Twice Daily Oral (Gavage) in Juvenile Mice." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 30.09.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Oncaspar - pegaspargase - EMEA/H/C/003789/II/0038 Les Laboratoires Servier, Rapporteur: Alexandre Moreau, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on the risk of osteonecrosis and to include it as an adverse drug reaction associated with pegaspargase use with an unknown frequency, following review of all available non-clinical, epidemiological and clinical data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest	Positive Opinion adopted by consensus on 13.01.2022.

QRD template version 10.2” Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 25.11.2021, 28.05.2021.	
Opsumit - macitentan - EMEA/H/C/002697/II/0044, Orphan Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, “C.I.4: Update of SmPC sections 4.8 and 5.1, based on the long-term follow-up data from SERAPHIN open-label (OL) study. SERAPHIN OL study was a long-term single-arm open-label extension study of the SERAPHIN double-blind (DB) study, to assess the safety and tolerability of macitentan in patients with symptomatic pulmonary arterial hypertension (PAH) that have completed the DB study or that experienced a morbidity event and for who a written approval to roll over into the OL study was obtained by the sponsor.” Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386/II/0004 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Update in section 4.8, Undesirable Effects, to present the pooled data from Perjeta and Phesgo studies. In addition to this, the MAH has taken the opportunity to introduce minor updates in the SmPC and the Package leaflet: • Update in section 9 of the SmPC to reflect the date of first authorisation • Editorial update in section 4 of the Package leaflet to add a space • Update in section 6 of the Package leaflet to adapt to the revised QRD Template v10.2” Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 21.10.2021, 22.07.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Pradaxa - dabigatran etexilate - EMEA/H/C/000829/II/0133 Boehringer Ingelheim International GmbH, Rapporteur: Thalia Marie Estrup Blicher, “- to remove rice cereal from the food compatibility list in the “Instructions for use”- “A) Administration of Pradaxa coated granules with soft foods” of the Package Leaflet for Pradaxa coated granules in sachets based on long-term	Positive Opinion adopted by consensus on 27.01.2022.

stability results and in-use food compatibility study." Opinion adopted on 27.01.2022.	
Prialt - ziconotide - EMEA/H/C/000551/II/0068 ESTEVE Pharmaceuticals GmbH, Rapporteur: Christophe Focke, "Update of section 4.2 of the SmPC to introduce a new posology regimen. The Package Leaflet to be updated accordingly. In addition, the MAH took the opportunity to update QRD template to v.10.2 Rev.1 and implement editorial changes in SmPC, PL and Labelling." Request for Supplementary Information adopted on 27.01.2022, 16.09.2021.	Request for supplementary information adopted with a specific timetable.
REKAMBYS - rilpivirine - EMEA/H/C/005060/II/0010 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 (table 6) of the SmPC in order to update the adverse reactions section, adding information regarding the majority of pyrexia events having a close temporal association with injections (reported within one week of injections). Based on the data analysis from clinical trials study 201585 FLAIR, 201585 ATLAS and 207966 ATLAS-2M. The Package Leaflet (section 4) is updated accordingly." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0014 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "C.I.4 - Update of section 5.1 of the SmPC in order to update efficacy information based on interim results (week 156) from studies M14-465 and M13-545; these are randomized phase 3, double blind studies to evaluate the long-term safety, tolerability and efficacy of upadacitinib in subjects with Rheumatoid Arthritis. In addition, the MAH took the opportunity to introduce editorial changes in section 5.1 of the SmPC." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Siklos - hydroxycarbamide - EMEA/H/C/000689/II/0051 Addmedica S.A.S., Rapporteur: Karin Janssen van Doorn, "C.I.3.b	Request for supplementary information adopted with a specific timetable.

Update of section 5.1 of the SmPC with the available paediatric data from the studies NOHARM and Escort HU according to the PAM-Leg 34." Request for Supplementary Information adopted on 13.01.2022.	
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0042 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include information on heterologous boosting using a 50 ug dose of Spikevax to boost subjects that have previously completed a primary vaccination series with any authorised COVID-19 vaccine, based on data from the DMID Study 21-0012, a Phase 1/2 heterologous SARS-CoV-2 vaccine dosing (mRNA-1273 booster) study of the various vaccines authorized in the US under Emergency Use Authorisation in participants ≥ 18 years old (NCT04889209). In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information." Request for Supplementary Information adopted on 27.01.2022, 16.12.2021.	Request for supplementary information adopted with a specific timetable. See 9.1
TAGRISSO - osimertinib - EMEA/H/C/004124/II/0045 AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.3 of the SmPC in order to reflect the outcome of the 104 Week Oral (Gavage) Carcinogenicity Study (507363) in the Rat submitted as recommended by the CHMP." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 16.12.2021, 11.11.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Tyverb - lapatinib - EMEA/H/C/000795/II/0072/G Novartis Europharm Limited, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add skin fissures to the list of adverse drug reactions (ADRs) with frequency common, following recently analysed safety data regarding skin fissures. The Package Leaflet is updated accordingly. The ATC code is also updated."	Positive Opinion adopted by consensus on 13.01.2022.

Opinion adopted on 13.01.2022.	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0088 MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 5.1 of the SmPC in order to include information about long-term durability of the immune protection against HBV infection based on study V419-013 A Hepatitis B Vaccine Challenge Study to Demonstrate the Durability of Protection Against Hepatitis B Virus Infection in Healthy Children Vaccinated Approximately 9 Years Previously With a 2- or 3-Dose Infant Series and Toddler Dose of Vaxelis (study report P013V419). In addition, the MAH is updating sections 4.7 and 4.8 of the SmPC to implement EMA proposed wording and a typo error. The MAH took the opportunity to update the list of local representatives in the PL and implement minor editorial changes in sections 4.8 and 6.6 of the SmPC and section 2 of the PL. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev. 1." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 11.11.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0031 AstraZeneca AB, Rapporteur: Sol Ruiz, "Submission of the final study report for MS1222-0002 "In Vitro Assay to Determine Release of Spike Protein From Transduced Cells" to fulfil the imposed study as reflected in Annex II of the product information and the RMP. As a result, Annex II of the product information is being updated to remove this study. The MAH is taking the opportunity to provide two additional studies linked to support the investigation on the platelet activation: the final study report for MS1222-0001 "Computational Prediction of Spike Protein Interaction with Platelet Factor 4 (PF4)" which is the first report requested within the required studies for "in vitro interaction of AZD1222 or spike protein with PF4 and/or platelets" as reflected in the	Request for supplementary information adopted with a specific timetable.

RMP; and the study report for 520447 "Investigative Vaccine Study in the Mouse" to evaluate spike protein levels and haematology parameters." Request for Supplementary Information adopted on 13.01.2022, 23.09.2021.	
Verzenios - abemaciclib - EMEA/H/C/004302/II/0021 Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to include second OS interim results from study MONARCH 3; this is a randomised, double blind, placebo-controlled phase 3 study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting." Opinion adopted on 27.01.2022.	Positive Opinion adopted by consensus on 27.01.2022.
Xagrid - anagrelide - EMEA/H/C/000480/II/0091 Takeda Pharmaceuticals International AG, Rapporteur: Alexandre Moreau, "C.I.4 Update of section 4.4 of the SmPC in order to add a new warning on the risks of fatal thrombotic complications associated with abrupt treatment discontinuation based on New Pharmacovigilance data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to perform a minor editorial change in section 4.2." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 09.12.2021, 02.09.2021.	Positive Opinion adopted by consensus on 27.01.2022.
WS2048 **Kalydeco- EMEA/H/C/002494/WS2048/0101** **Symkevi- EMEA/H/C/004682/WS2048/0030** Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Rhea Fitzgerald, "Update of the Product information to provide the final clinical study report (CSR) Part A of study VX17-661-116 (A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With	Positive Opinion adopted by consensus on 27.01.2022.

Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation). Consequently the SmPC sections 4.2, 4.5, 4.8 and 5.1 and the package leaflet are updated accordingly. The RMP is also updated." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 14.10.2021, 24.06.2021.	
WS2156 **Nuwiq-EMEA/H/C/002813/WS2156/0047** **Vihuma-EMEA/H/C/004459/WS2156/0029** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from study GENA-99 including the integrated analysis report of studies GENA-99, GENA-13, GENA-15, GENA-21, GENA-21b and GENA-100. GENA-99 is a Prospective, multinational, non-interventional post-authorisation study to document the long-term immunogenicity, safety and efficacy of Human-cl rhFVIII (simoctocog alfa) in patients with haemophilia A treated in routine clinical practice." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 28.10.2021.	Positive Opinion adopted by consensus on 27.01.2022.
WS2170 **OPDIVO-EMEA/H/C/003985/WS2170/0114** **Yervoy-EMEA/H/C/002213/WS2170/0094** Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy information based on 5 years follow-up OS data from study CA209214; this is a phase 3, randomised, open-label study in previously untreated, intermediate/poor risk advanced RCC." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2174 **Hexacima-EMEA/H/C/002702/WS2174/0123** **Hexyon-EMEA/H/C/002796/WS2174/0127** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus, "Update of section 4.5 of the SmPC in	Request for supplementary information adopted with a specific timetable.

order to add drug-drug interaction information regarding the co-administration of Hexyon / Hexacima with varicella vaccines based on a re-analysis of the A3L15 clinical trial varicella serological data, submitted in the initial CTD dossier. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct some typo errors in the SmPC and PL." Request for Supplementary Information adopted on 20.01.2022.	

B.5.3. CHMP-PRAC assessed procedures

Alecensa - alectinib - EMEA/H/C/004164/II/0037/G Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to add a new warning, dose modification advice and description of the known ADR haemolytic anaemia based on an updated Drug Safety Report; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial updates in the Maltese and Romanian product information. Moreover, the ATC code for alectinib is being updated from L01XE36 to L01ED03." Request for Supplementary Information adopted on 27.01.2022.	Request for supplementary information adopted with a specific timetable.
Alunbrig - brigatinib / brigatinib - EMEA/H/C/004248/II/0037 Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study AP26113-13-301 listed as a PAES in the Annex II; this is a randomised, open-label, multicentre phase III study comparing brigatinib versus crizotinib in patients with advanced ALK-positive NSCLC who have not previously received ALK-directed therapy; The RMP version 5.4 has also been submitted." Request for Supplementary Information adopted on 13.01.2022, 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Bosulif - bosutinib -	Positive Opinion adopted by consensus on

EMEA/H/C/002373/II/0050/G Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect results from the studies B1871039 (SOB) and B1871040 (category 3); study B1871039 is A Phase 4 Safety and Efficacy Study of Bosutinib in Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukaemia Previously Treated With One or More Tyrosine Kinase Inhibitors and study B1871040 is An Open-Label Bosutinib Treatment Extension Study for Subjects With Chronic Myeloid Leukaemia (CML) who Have Previously Participated in Bosutinib Studies B1871006 or B1871008. The Package Leaflet is updated accordingly. The MAH request deletion of the SOB from annex II of the PI and request consideration for switch of the Conditional Marketing Authorisation to a full Marketing Authorisation. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives for Belgium, Luxemburg, Germany and Northern Island in the Package Leaflet. The MAH is also asking the deletion of the product from the additional monitoring list." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 16.12.2021, 16.09.2021.	27.01.2022. See 9.1
Cablivi - caplacizumab - EMEA/H/C/004426/II/0035, Orphan Ablynx NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on increased risk of bleeding and add blood and lymphatic system disorders to the list of adverse drug reactions (ADRs) with frequency not known based on a safety evaluation report; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Deltyba - delamanid - EMEA/H/C/002552/II/0053, Orphan Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Laurence de Fays, "Update of section 4.8 of the SmPC in	Request for supplementary information adopted with a specific timetable.

order to update the list of adverse drug reactions (ADRs table) following the development of an improved methodology to identify relevant ADRs likely attributable to delamanid. The section 4 of the Package Leaflet is updated accordingly. The RMP version 3.6 has also been submitted." Request for Supplementary Information adopted on 13.01.2022.	
ELZONRIS - tagraxofusp - EMEA/H/C/005031/II/0009, Orphan Stemline Therapeutics B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, "Submission of the final report from study 20255431 (CRL-263114) 'Characterization of fixed choroid plexus samples from primate study MPI-2231-007 by Immunohistochemistry with DT, CD123, IL-3 and IgG' (MEA002) listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions. The RMP version 2.0 has also been submitted." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable. See 9.1
Enbrel - etanercept - EMEA/H/C/000262/II/0246 Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of section 5.1 of the SmPC in order to update clinical information based on final results obtained from the clinical paediatric study B1801023 (CLIPPER 2). The RMP version 7.5 has also been submitted." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Galafold - migalastat - EMEA/H/C/004059/II/0034, Orphan Amicus Therapeutics Europe Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga, "To update sections 4.8, 5.1 and 5.2 of the SmPC based on final results from study AT1001-020 listed as category 3 in the RMP. Study AT1001-020-is a Phase 3b, 2-stage, open-label, uncontrolled, multicentre study to evaluate the safety, pharmacokinetic, pharmacodynamic and efficacy	Positive Opinion adopted by consensus on 13.01.2022.

of migalastat treatment in paediatric subjects 12 to < 18 years of age and weighing ≥ 45 kg with Fabry disease and with amenable GLA variants. The updated RMP version 7.0 has also been submitted. The final results of study AT1001-020, which is involving paediatric patients, are submitted in fulfilment of Article 46 of Regulation 1901/2006, as amended. In addition, the MAH took the opportunity to introduce some minor editorial changes to the SmPC and Package Leaflet and bring the PI in line with the latest QRD template v. 10.2." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 30.09.2021.	
GIVLAARI - givosiran - EMEA/H/C/004775/II/0006, Orphan Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Type II C.I.4: Update of SmPC section 4.8 to add 'blood homocysteine increase' as a new ADR and update to SmPC section 4.4 to add a related warning. The package leaflet is being updated accordingly. RMPv1.1 is also being submitted: consequences of blood homocysteine increase is being added as a new important potential risk, the clinical and post-marketing exposure is being updated and the due dates for ALN-AS1-002 and ALN-AS1-003 final study reports are being postponed. In addition, the MAH took the opportunity to make editorial changes to the Product Information in other EU languages and to update the contact number of the local representatives for Malta and Cyprus." Request for Supplementary Information adopted on 13.01.2022, 28.10.2021, 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0069 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of the SmPC section 4.4 to include information on fatal and serious cardiac arrythmias and cardiac failure, relevant warnings and periodical monitoring of patients, following a safety assessment for increased risk of sudden death/cardiac death with the use of ibrutinib. Section 2 of the PL has been updated	Request for supplementary information adopted with a specific timetable. See 9.1

accordingly. Typographical errors have been corrected throughout the PI. The revised RMP version 11 has been submitted." Request for Supplementary Information adopted on 27.01.2022.	
Lemtrada - alemtuzumab - EMEA/H/C/003718/II/0038 Sanofi Belgium, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, "Update of sections 4.4 and 4.8 of the SmPC to add Adult Onset Still's Disease (AOSD) to the list of adverse drug reactions (ADRs) with frequency not known, based on a signal validated during a routine pharmacovigilance surveillance; the Package Leaflet is updated accordingly. The MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP v.9.0 submitted to include AOSD; and to remove the PASS study OBS13436 (Pregnancy Registry)." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
Mavenclad - cladribine - EMEA/H/C/004230/II/0020 Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.4 Type II Update of sections 4.2 and 4.4 of the SmPC in order to change posology recommendations by adding an advice on preventive measures to avoid liver injury and to add a new warning on liver function and liver injury based on a review of post-approval data in MAH's safety database, non-clinical and clinical trial data and scientific literature (cladribine and liver injury and epidemiological data on hepatic injury in MS). The Package Leaflet is updated accordingly. The RMP version 1.6 has also been submitted." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 02.09.2021, 10.06.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Naglazyme - galsulfase - EMEA/H/C/000640/II/0086 BioMarin International Limited, Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins, "C.I.11.b variation to update the RMP to version 6.4 to remove gastrointestinal haemorrhage, hepatic impairment and thrombocytopenia from the list of important	Positive Opinion adopted by consensus on 27.01.2022. See 9.1

potential risks. This proposed update is supported by the submission of the final report from the MPS VI Clinical Surveillance Program (CSP) listed as a Specific Obligation (SOB002) in the Annex II of the Product Information for this MAA under exceptional circumstances. This observational CSP was undertaken to characterise the natural progression of MPS VI, to evaluate the long-term safety and efficacy data from Naglazyme treatment, to collect information on the effect of Naglazyme treatment on lactation, growth and development of infants of Naglazyme treated mothers, and to evaluate the effects of Naglazyme treatment on children under 5 years of age." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 16.09.2021.	
Ontruzant - trastuzumab - EMEA/H/C/004323/II/0036 Samsung Bioepis NL B.V., Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Submission of the final report from clinical study (SB3-G31-BC-E) listed as a category 3 study in the RMP. This is an observational cohort study assessing the long-term cardiac safety (for Cardiac Safety and Survival Cohort) and survival (Survival Only Cohort and Cardiac Safety and Survival Cohort) in patients who received treatment in study SB3-G31-BC. The RMP version 5.0 is also provided." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 02.09.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Rydapt - midostaurin - EMEA/H/C/004095/II/0018/G, Orphan Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.4, Update of the SmPC in section 4.5 in order to add drug-drug interaction information with P-gp, BCRP, CYP2D6, substrates (digoxin, rosuvastatin, and dextromethorphan), based on final results from study CPKC412A2121, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section	Positive Opinion adopted by consensus on 27.01.2022.

5.2 of the SmPC and the Package Leaflet are updated accordingly. (MEA 005.3)
C.I.4, Update of the SmPC in section 4.5 in order to add drug-drug interaction information with CYP2B6, CYP2C8, CYP3A4 substrates, based on final results from study CPKC412A2122, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section 5.2 of the SmPC and the Package Leaflet is updated accordingly. (MEA 007.2)
C.I.4 Update of the SmPC in section 4.5 in order to add drug-drug interaction information with oral contraceptives and section 4.6 to update information on pregnancy and contraception based on final results from study CPKC412A2123, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; the Package Leaflet is updated accordingly. (MEA 008.2)
C.I.4 Update of the SmPC in section 5.2 in order to update pharmacokinetic information on OATP1B1 transporters based on final results from PBPK modelling study DMPK R2000528 listed as category 3 studies in the RMP (MEA 009);
C.I.4 Update of the SmPC in section 4.2 in order to amend posology instructions, section 4.4 to amend an existing warning and section 5.2 to update pharmacokinetic information for patients with severe hepatic impairment, based on final results from study CPKC412A2116 listed as category 3 study in the RMP. This is an open label, multiple dose study to evaluate the PK of midostaurin in subjects with mild, moderate and severe hepatic impairment compared to matched healthy subjects; (MEA010)
The RMP version 6.0 has also been submitted.
In addition, MAH takes this opportunity to introduce minor changes to edit the wording related to the ethanol excipient in the Package Leaflet, according the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668), by rounding the volume of alcohol to the next integer number, i.e. from 16.9 to 17 ml.
The requested group of variations proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the

Risk Management Plan (RMP)." Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 11.11.2021, 24.06.2021.	
TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/II/0069/G Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "C.I.4 type II variation: Update of section 4.8 of the SmPC in order to add rhinorrhoea to the list of adverse drug reactions (ADRs) with frequency unknown based on a systematic review of information from clinical and non-clinical studies, post-marketing data and scientific literature. The Package Leaflet has been updated accordingly. C.I.4 type II variation: Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 109MS303 (ENDORSE) listed as a category 3 study in the RMP. This is a dose-blind, multicentre, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with Relapsing-Remitting Multiple Sclerosis. The RMP version 11.1 has also been submitted." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 28.10.2021, 02.09.2021, 08.07.2021, 06.05.2021, 14.01.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Tremfya - guselkumab - EMEA/H/C/004271/II/0031 Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski, "C.I.4 Update of sections 4.8 and 5.1 of the SmPC based on the 2-year data from the psoriatic arthritis Phase 3 clinical study CNTO1959PSA3002 and to remove this study as an additional Pharmacovigilance activity from the Risk Management Plan (RMP). The RMP version 8.2 is accepted." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 28.10.2021.	Positive Opinion adopted by consensus on 13.01.2022.
Tresiba - insulin degludec - EMEA/H/C/002498/II/0054 Novo Nordisk A/S, Rapporteur: Kristina Dunder, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Annika Folin, "Update of sections	Positive Opinion adopted by consensus on 13.01.2022.

4.6 and 5.1 of the Summary of product characteristics in order to include new clinical data from the pregnancy trial EXPECT conducted for Tresiba. This was a multi-centre, randomised, active controlled trial comparing the efficacy and safety of Tresiba once daily with insulin detemir once or twice daily both in combination with insulin aspart 2-4 times daily with meals in pregnant women or women who intended to become pregnant, all with type 1 diabetes. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor administrative changes. The RMP version 9.0 is also submitted." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 02.12.2021.	
WS2141 **Ozempic-** **EMEA/H/C/004174/WS2141/0024** **Rybelsus-** **EMEA/H/C/004953/WS2141/0018** Novo Nordisk A/S, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Annika Folin, "Submission of the final report from study NN9535-4386 (SUSTAIN-11), listed as a category 3 study in the RMP. This is a 52-week, multi-centre, multinational, open-label, active controlled, two armed, parallel, randomised trial undertaken to investigate the effect on glycaemic control, body weight, safety and health-related quality of life of once-weekly semaglutide s.c. vs insulin aspart three times daily, both as add-on to metformin and optimised insulin glargine U100 treatment in subjects with inadequately controlled T2DM. The RMP version 7.0 has also been submitted." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.

B.5.4. PRAC assessed procedures

PRAC Led **AUBAGIO - teriflunomide -** **EMEA/H/C/002514/II/0038** sanofi-aventis groupe, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the	Positive Opinion adopted by consensus on 13.01.2022.

final PASS OBS12753 study report listed as a category 3 study in the RMP. This is a prospective cohort study of long-term safety of teriflunomide in multiple sclerosis patients in Europe. The updated RMP v 7.3 is agreed." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 02.12.2021, 30.09.2021.	
PRAC Led **Calquence - acalabrutinib - EMEA/H/C/005299/II/0011** AstraZeneca AB, Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić, PRAC-CHMP liaison: Selma Arapovic Dzakula, "Submission of an updated RMP version 3 in order to add hepatotoxicity as an important potential risk to the safety concerns." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0080** BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of section 4.4 of the SmPC in order to amend an existing warning on anxiety-related reactions to add hypoaesthesia and paraesthesia and remove tingling sensations following the outcome of the Post-Authorisation Measure MEA-002.8 (EMEA/H/C/005735/MEA/002.8, dated 30 September 2021). Update of section 4.8 of the SmPC in order to add hypoaesthesia and paraesthesia to the list of adverse drug reactions (ADRs) with frequency 'not known' following the outcome of the Post-Authorisation Measure MEA-002.8 (EMEA/H/C/005735/MEA/002.8, dated 30 September 2021). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 02.12.2021.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0087**	Request for supplementary information adopted with a specific timetable.

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 2.6 to include data from the booster/third dose, including data in patients who have undergone a solid organ transplantation, following the outcomes of procedures EMEA/H/C/005735/II/0062 (third dose in immunocompromise as part of the primary vaccination) and EMEA/H/C/005735/II/0067 (booster dose). The MAH takes the opportunity to update the RMP regarding the discontinuation of enrolment in study C4591015 (phase 2/3 study to evaluate the safety, tolerability, and immunogenicity in healthy pregnant women 18 years of age and older) and the CSR milestones." Request for Supplementary Information adopted on 13.01.2022.	
PRAC Led **COVID-19 Vaccine Janssen - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein - EMEA/H/C/005737/II/0029** Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP version 3.1 in order to upgrade the important potential risk of venous thromboembolism (VTE) to an important identified risk as an outcome of the procedure MEA-32, addition of the clinical trial VAC31518COV3003 and update of study VAC18193RSV2008 as additional pharmacovigilance activities to further characterise the important identified risks of Thrombosis with thrombocytopenia syndrome (TTS), thrombocytopenia (including immune thrombocytopenia) and VTE as an outcome of MEA 14.4. The MAH took the opportunity to include other minor updates in the RMP. In addition, the MAH consolidated in RMP version 3.1 the updates made in the RMP as part of the approved procedure EMEA/H/C/005737/II/0018 and procedure EMEA/H/C/005737/II/0029." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **COVID-19 Vaccine Janssen - adenovirus type 26 encoding the sars-cov-2 spike**	Positive Opinion adopted by consensus on 13.01.2022.

glycoprotein - EMEA/H/C/005737/II/0035 Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of sections 4.4 and 4.8 of the SmPC in order to add transverse myelitis to the list of warnings and precautions and to the list of adverse drug reactions (ADRs) with frequency 'not known' based on the PRAC request from the post-authorisation measures MEA 14.5 and MEA 14.6 (6th and 7th Monthly Summary Safety Report covering the months of August 2021 and September 2021, respectively). The Package Leaflet is updated accordingly. Update of section 4.4 of the SmPC in order to amend the wording on Thrombosis and thrombocytopenia syndrome (TTS) following the PRAC request from the post-authorisation measure MEA 14.5. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement an editorial Quality review document (QRD) comment in the labelling following procedure EMEA/H/C/005737/II/014." Opinion adopted on 13.01.2022.	
PRAC Led **Cystadrops - mercaptamine - EMEA/H/C/003769/II/0023, Orphan** Recordati Rare Diseases, Rapporteur: Kristina Dunder, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.11 for RMP: Submission of an updated RMP version 1.4 in order to align with the new RMP format according to GVP Rev.2 and to remove a missing information from the list of safety concerns." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Evoltra - clofarabine - EMEA/H/C/000613/II/0075** Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of section 4.6 of the SmPC following a request during EMEA/H/C/PSUSA/00000805/202012 to revise section 4.6 of the SmPC and corresponding sections in the PIL considering the recommendations of the Safety Working	Positive Opinion adopted by consensus on 13.01.2022.

Party as reflected in the 'SWP recommendations on the duration of contraception following the end of treatment with a genotoxic drug' and available data. The proposed update of the product information should be based on a detailed scientific rationale from all available data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.2" Opinion adopted on 13.01.2022.	
PRAC Led **Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0023** Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.6 of the SmPC in order to update information on Pregnancy Registry 130_110B, listed as a category 3 study in the RMP. The PL is updated accordingly. The RMP version 3.1 has also been submitted in order to update information related to the pregnancy study, clinical and post-marketing exposure." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 02.12.2021.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **Hemlibra - emicizumab - EMEA/H/C/004406/II/0025** Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Update of sections 4.4, 4.8 and 5.1 of the Product information concerning immunogenicity and loss of efficacy due to anti-emicizumab antibodies. The RMP (v.3.0) is proposed to be updated accordingly." Request for Supplementary Information adopted on 13.01.2022, 02.12.2021, 02.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Hemlibra - emicizumab - EMEA/H/C/004406/II/0028** Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando	Request for supplementary information adopted with a specific timetable.

Genazzani, "Submission of the final study report for BO40853 (Hemlibra Survey to Prescribers and Patients/Carers to Evaluate Awareness, Knowledge, and Compliance to Additional Risk Minimisation Measures, listed as a category 3 study in the RMP). An updated RMP (version 4.0) is presented in support of this application." Request for Supplementary Information adopted on 13.01.2022, 02.12.2021.	
PRAC Led **Moventig - naloxegol - EMEA/H/C/002810/II/0034** Kyowa Kirin Holdings B.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Submission of the final report from the observational Post Authorisation Safety Study (PASS)- Drug Utilisation in Selected European Populations (D3820R00006), listed as a category 3 study in the Risk Management Plan (RMP). The RMP version 7.1 is accepted." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted on 28.10.2021.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **Obizur - susoctocog alfa - EMEA/H/C/002792/II/0043** Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from US PASS 241302 study, EUPAS register Number EUPAS36659, listed as a category 3 study in the RMP. This is a post-marketing non-interventional safety evaluation of Obizur in the treatment of bleeding episodes for patients with acquired haemophilia A (AHA).The primary objective is to determine the incidence of therapy-related serious adverse events (SAEs) in patients with AHA who are prescribed and treated with OBIZUR in routine clinical practice. The RMP version 5.0 has also been submitted and endorsed." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **OFEV - nintedanib - EMEA/H/C/003821/II/0046** Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, PRAC Rapporteur:	Request for supplementary information adopted with a specific timetable.

Nikica Mirošević Skvrce, PRAC-CHMP liaison: Selma Arapovic Dzakula, "C.I.11 for RMP: Submission of an updated RMP version 11.0 in order to fulfil a request made in the renewal (EMEA/H/C/003821/R/0025) to remove the following safety concerns (Modules SIV, SVII, SVIII; Parts III, V, VI; Appendices 4, 8) : 1-Important identified risks: Diarrhoea, Liver enzyme and bilirubin elevations including DIL, Bleeding, Myocardial infarction); 2-Important potential risks: Venous thromboembolism, Arterial thromboembolism excluding myocardial infarction, Perforation, Hepatic failure, Treatment of pregnant women and teratogenicity, Cardiac failure; 3- Missing information: Treatment of patients with moderate or severe hepatic impairment (Child Pugh B/C), Treatment of Black patients, Treatment of patients with healing wounds, Treatment of patients with severe renal impairment or end-stage renal disease, Treatment of patients receiving full-dose therapeutic anticoagulation, Treatment of breastfeeding women. Moreover, it is updated ATC code (Part I) and post-marketing exposure (Module SV)." Request for Supplementary Information adopted on 13.01.2022.	
PRAC Led **Olumiant - baricitinib - EMEA/H/C/004085/II/0031** Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "C.I.4 - Update of section 4.4 of the SmPC in order to add new warnings on Major Adverse Cardiac Events (MACE) and amend existing warning on Malignancy and Venous thromboembolism (VTE) following the request made in PSUSA (EMEA/H/C/PSUSA/00010578/202102) and based on interim results from study I4V-MC-B023; this is a retrospective observational study to compare baricitinib relative to the standard of care. The Package Leaflet is updated accordingly. The RMP version 13.1 has also been submitted. In addition, the MAH has submitted a proposal for a DHPC and communication plan." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 13.01.2022.	
PRAC Led **Otezla - apremilast - EMEA/H/C/003746/II/0039** Amgen Europe B.V., Rapporteur: Peter Kiely, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13-Submission of the final study report (CSR) from UK Clinical Practice Research Database (CPRD), listed as a category 3 study in the RMP. This is an observational study to assess the long-term data of apremilast in patients with psoriasis and psoriatic arthritis. The RMP version 14.0 has also been submitted." Request for Supplementary Information adopted on 13.01.2022, 30.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Remicade - infliximab - EMEA/H/C/000240/II/0231** Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report of the Remicade AntiRheumatic Therapy in Sweden (ARTIS) registry study. The ARTIS registry study was performed to fulfil a post-authorisation measure in the RMP for Remicade. The updated RMP v20.1. has also been submitted, including revisions agreed in previous procedures." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/II/0024** sanofi-aventis groupe, Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final Clinical Study Report of the Category 3 PASS INSLIC08571, a 'Survey to evaluate the knowledge and understanding of the key safety messages in the healthcare professional guide and the patient guide'. The provision of the final survey results addresses post-authorisation measure (PAM) MEA 002.7. The updated RMP version 6.1 was agreed during the procedure." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 13.01.2022.

on 30.09.2021.	
PRAC Led **Tegsedi - inotersen - EMEA/H/C/004782/II/0026, Orphan** Akcea Therapeutics Ireland Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Submission of an updated RMP version 3.0 to remove carcinogenicity in rats as missing information, add a targeted questionnaire as routine pharmacovigilance measure and a patient alert card as additional risk minimisation for liver transplant rejection. To add 'injection site reactions' and 'immunogenicity' as risks not considered important for inclusion in the summary of safety concerns, and to update the patient alert card with additional warnings on hepatic monitoring and ocular toxicity. Further sections of the RMP are updated." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Temodal - temozolomide - EMEA/H/C/000229/II/0095** Merck Sharp & Dohme B.V., Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Update of the RMP to version 6.1. to remove all the safety concerns (important identified risks, important potential risks and missing information). The deletion of the safety concerns is based on the guidance EU GVP Module V (Revision 2)." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **TRISENOX - arsenic trioxide - EMEA/H/C/000388/II/0076** Teva B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of section 4.6 of the SmPC in order to update information on pregnancy and contraception in male patients following the decision and discussion made for EMEA/H/C/PSUSA/00000235/202009 and to add an appropriate period of abstinence for breastfeeding during use of trisenox. The Package Leaflet is updated accordingly." Opinion adopted on 13.01.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 13.01.2022.

on 02.12.2021.	
PRAC Led **Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0055** AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Update of section 4.4 of the SmPC in order to update the warning on thrombosis with thrombocytopenia syndrome to indicate that the frequency after the second dose is lower than after the first dose based on the post-marketing data. The package leaflet is updated accordingly. The MAH took the opportunity to include editorial updates in the product information." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
PRAC Led **Zessly - infliximab - EMEA/H/C/004647/II/0020** Sandoz GmbH, Rapporteur: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the updated RMP version 3.0 to remove the RABBIT registry as an additional pharmacovigilance activity in alignment with the updated version of the reference product Remicade RMP (v19) and to remove the BADBIR registry as an additional pharmacovigilance activity." Request for Supplementary Information adopted on 13.01.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS2185** **Entresto-** **EMEA/H/C/004062/WS2185/0041** **Neparvis-** **EMEA/H/C/004343/WS2185/0039** Novartis Europharm Limited, Lead PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, "To provide an updated RMP in response to the assessment report for procedure EMEA/H/C/WS1830. In addition, the following changes have been introduced: - change to the agreed milestone for study CLCZ696B2320 (EU PASS category 3), to update the date for the submission of the final report ; - update of section 8.3.1 (Presentation of important identified risks and important	Request for supplementary information adopted with a specific timetable.

potential risks); - updated exposure and post-marketing data have been provided for the data lock point of PSUR 9 (31-Jul-21).” Request for Supplementary Information adopted on 13.01.2022.	

B.5.5. CHMP-CAT assessed procedures

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0002, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 27.01.2022, 21.01.2022. Request for Supplementary Information adopted on 05.11.2021.	Positive Opinion adopted by consensus on 27.01.2022.
Luxturna - voretigene neparvovec - EMEA/H/C/004451/II/0026/G, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 21.01.2022.	Request for supplementary information adopted with a specific timetable.
Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - EMEA/H/C/005102/II/0016, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 21.01.2022.	Request for supplementary information adopted with a specific timetable.
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0019/G, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege Opinion adopted on 27.01.2022, 21.01.2022. Request for Supplementary Information adopted on 05.11.2021.	Positive Opinion adopted by consensus on 27.01.2022.
WS2181	Positive Opinion adopted by consensus on

Tecartus- **EMEA/H/C/005102/WS2181/0014** **Yescarta-** **EMEA/H/C/004480/WS2181/0044** Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 16.12.2021.	27.01.2022.

B.5.6. CHMP-PRAC-CAT assessed procedures

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0010, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Annika Folin, "Update of section 5.1 of the SmPC in order to update efficacy information based on 24 month follow-up data from the pivotal study submitted during initial (BB2121-MM-001: A Phase 2, Multicentre Study to determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma) listed as a specific obligation in the Annex II and in the RMP; The annex II is updated with the proposed deletion of the relevant SOB. The RMP version 1.1 has also been submitted." Opinion adopted on 27.01.2022.	Positive Opinion adopted by consensus on 27.01.2022.

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and work-sharing procedures of type I variations

WS2111/G **Eucreas-** **EMEA/H/C/000807/WS2111/0089/G** **Icandra-** **EMEA/H/C/001050/WS2111/0092/G** **Zomarist-** **EMEA/H/C/001049/WS2111/0091/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder	Positive Opinion adopted by consensus on 13.01.2022.

Opinion adopted on 13.01.2022.	
WS2140 **Infanrix hexa-** **EMEA/H/C/000296/WS2140/0307** GlaxoSmithKline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2155 **Ambirix-** **EMEA/H/C/000426/WS2155/0118** **Fendrix-** **EMEA/H/C/000550/WS2155/0077** **Twinrix Adult-** **EMEA/H/C/000112/WS2155/0153** **Twinrix Paediatric-** **EMEA/H/C/000129/WS2155/0154** GlaxoSmithKline Biologicals SA, Lead Rapporteur: Christophe Focke, "To add the warning on sodium to sections 2 and 4.4 of the SmPC; section 3 of Labelling and section 2 of Package leaflet to bring the annexes in line with the excipients guideline. In addition, the QRD template v10.2 update is implemented. Contact details of local representatives are updated as follows: - Ambirix in Belgium, Croatia, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Romania, Slovenia, Slovakia, and United Kingdom (Northern Ireland); - Fendrix in Belgium, Croatia, Cyprus, Estonia, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Norway, Romania, Slovenia, Slovakia, Spain and United Kingdom (Northern Ireland); - Twinrix Adult in Belgium, Croatia, Cyprus, Estonia, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Norway, Romania, Slovenia, Slovakia, Spain and United Kingdom (Northern Ireland); - Twinrix Adult in Belgium, Croatia, Cyprus, Estonia, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Norway, Romania, Slovenia, Slovakia, Spain and United Kingdom (Northern Ireland)." Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2162 **Prezista-**	Positive Opinion adopted by consensus on

EMEA/H/C/000707/WS2162/0113 Rezolsta-EMEA/H/C/002819/WS2162/0044 Symtuza-EMEA/H/C/004391/WS2162/0038 Janssen-Cilag International NV, Lead Rapporteur: Johann Lodewijk Hillege, "To update for the 3 Darunavir products (PREZISTA, REZOLSTA and Symtuza), section 4.3, section 4.4 (PREZISTA 100 mg/ml, 400 mg and 800 mg) and section 4.5 of each SmPC to emphasise that the lists of medications in the Contraindications and in the Interactions sections are not comprehensive and are to be considered as examples. The Package Leaflets are updated accordingly. The MAH also has taken the opportunity to include several minor changes as follows: - an update in section 4.5 of the SmPC and section 2 of the Patient leaflet of Symtuza to include information about elbasvir and grazoprevir, in order to align with the info provided in the PREZISTA and REZOLSTA labels (as approved in Feb 2017 in procedure WS1107/G); - correcting the capitalization of 'wort' in St. John's Wort; - adding the prefix for Belgian postcodes to the addresses in the respective Package Leaflets." Opinion adopted on 13.01.2022.	13.01.2022.
WS2173 HBVAXPRO-EMEA/H/C/000373/WS2173/0073 Vaxelis-EMEA/H/C/003982/WS2173/0091 MCM Vaccine B.V., Lead Rapporteur: Christophe Focke Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2175 Corbilta-EMEA/H/C/002785/WS2175/0026 Levodopa/Carbidopa/Entacapone Orion-EMEA/H/C/002441/WS2175/0034 Stalevo-EMEA/H/C/000511/WS2175/0096 Orion Corporation, Lead Rapporteur: Outi Mäki-Ikola, "To add Sodium warning to sections 2 and 4.4 of the SmPC; section 3 of Labelling and section 2 of Package leaflet to Stalevo and its duplicates Corbilta and Levodopa/Carbidopa/Entacapone Orion.	Positive Opinion adopted by consensus on 27.01.2022.

QRD template v10.2 update is implemented for Stalevo and Levodopa/Carbidopa/Entacapone Orion. Contact details of local representatives are updated as follows: - Stalevo in France and United Kingdom (Northern Ireland); - Corbilta in France; - Levodopa/Carbidopa/Entacapone Orion in Lithuania, Estonia, Ireland, Latvia and United Kingdom (Northern Ireland). Additionally, missing non-breaking spaces added, wherever applicable according to EMA guidance 'Compilation of QRD decisions on stylistic matters in product information'. Minor linguistic and typographical corrections have been performed in several languages as follows: Stalevo: CS, DE, EL, EN, ES, ET, FR, HR, HU, IS, LT, LV, MT, NL, NO, PL, PT, RO, SK and SL. Corbilta: CS, DA, DE, EL, EN, ES, ET, FR, HR, HU, IS, LT, LV, MT, NL, NO, PL, PT, RO, SK, SL and SV. Levodopa/Carbidopa/Entacapone Orion: CS, DA, DE, EL, EN, ES, ET, FR, HR, HU, IS, LT, LV, MT, NL, PL, PT, RO, SK and SL." Opinion adopted on 27.01.2022.	
WS2186 **Blitzima-EMEA/H/C/004723/WS2186/0050** **Truxima-EMEA/H/C/004112/WS2186/0053** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2208 **Blitzima-EMEA/H/C/004723/WS2208/0051** **Truxima-EMEA/H/C/004112/WS2208/0054** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz Opinion adopted on 13.01.2022.	Positive Opinion adopted by consensus on 13.01.2022.
WS2209 **Blitzima-EMEA/H/C/004723/WS2209/0052** **Truxima-EMEA/H/C/004112/WS2209/0055** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz	Positive Opinion adopted by consensus on 27.01.2022.

Opinion adopted on 27.01.2022.

B.5.9. Information on withdrawn type II variation / WS procedure

LEDAGA - chlormethine - EMEA/H/C/002826/II/0027, Orphan Helsinn Birex Pharmaceuticals Limited, Rapporteur: Sinan B. Sarac, "Update of section 4.2 of the SmPC in order to allow flexibility in the starting frequency of the treatment based on current clinical practice; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 20.05.2021. Withdrawal request submitted on 11.01.2022.	The MAH withdrew the procedure on 11.01.2022.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

ublituximab - EMEA/H/C/005914 treatment of relapsing forms of multiple sclerosis (RMS)
dimethyl fumarate - EMEA/H/C/005950 treatment of multiple sclerosis
follitropin delta - EMEA/H/D/006065 In vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and plasma
trastuzumab - EMEA/H/C/005769 treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)
sirolimus - EMEA/H/C/005896, Orphan Plusultra pharma GmbH, Treatment of angiofibroma associated with tuberous sclerosis complex
tremelimumab - EMEA/H/C/004650 treatment of adults with metastatic NSCLC with no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations

paclitaxel - EMEA/H/C/005997 treatment of metastatic breast cancer	
parsaclisib - EMEA/H/C/005893, Orphan Incyte Biosciences Distribution B.V., Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL).	
(1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973 treatment of COVID-19	See 2.1 and 3.1
tolvaptan - EMEA/H/C/005961 treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH)	

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Adcirca - tadalafil - EMEA/H/C/001021/X/0035/G Eli Lilly Nederland B.V., Informed Consent of Cialis, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 6 months to 17 years) based on study 4 (H6D-MC-LVHV [LVHV]) - A 24-week placebo-controlled efficacy and safety study with an open-label long-term extension phase. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The paediatric indication is applicable to the new and all existing presentations. The Package Leaflet and Labelling are updated accordingly. Furthermore, the PI is brought in line with the latest QRD template and editorial changes have been implemented. The RMP (version 9.1) is updated in accordance."	
Betmiga - mirabegron - EMEA/H/C/002388/X/0039/G Astellas Pharma Europe B.V., Rapporteur: Maria	

Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, "Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation (C.I.6.a) to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.0) is updated in accordance."

Byfavo - remimazolam - EMEA/H/C/005246/X/0002

PAION Netherlands B.V., Rapporteur: Bruno Sepodes, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Rhea Fitzgerald, "Extension application to introduce a new pharmaceutical form associated with new strength (50 mg powder for concentrate for solution for injection/infusion). The new presentation is indicated to include the intravenous induction and maintenance of general anaesthesia (GA) in adults for Byfavo 50 mg, based on final results from two pivotal trials: Study ONO-2745-05, a phase IIb/III, single-blind, randomised, parallel-group study assessing safety and efficacy in induction and maintenance of anaesthesia in ASA I/II patients (general surgery), and study CNS-7056-022, a phase III, randomized, propofol controlled, parallel group, confirmatory single-blind efficacy and safety trial during induction and maintenance of anaesthesia in ASA III/IV patients.
A new combined version of the SmPC, labelling and Package Leaflet solely for the 50 mg strength and the GA indication is provided accordingly.
Version 1.1 of the RMP has also been submitted.
As part of the application, the MAH also requests an extension of the market protection by one additional year."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Dupixent - dupilumab - EMEA/H/C/004390/X/0057

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus

Skyrizi - risankizumab -

EMEA/H/C/004759/X/0020/G

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Peter Kiely, PRAC Rapporteur: Liana Gross-Martirosyan, "Extension application to:
- introduce a new pharmaceutical form (concentrate for solution for infusion), a new strength (600 mg) and a new route of administration (intravenous use)
- add a new strength of 360 mg (150 mg/ml) for risankizumab solution for injection (in cartridge) for subcutaneous use.
The above new presentations are indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.
The RMP (version 4.0) is updated in accordance."

Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/X/0101/G

ViiV Healthcare B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber, "Extension application to introduce a new pharmaceutical form associated with new strength (5 mg/60 mg/30 mg dispersible tablet). The new presentation is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected children weighing at least 14 kg to less than 25 kg.
This extension application is grouped with a type II variation (C.I.6.a) to include treatment of children weighing at least 25 kg for the already approved film-coated tablets for Triumeq (EU/1/14/940/001-002); as a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 19) is updated in accordance."

Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0008/G

Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Sonja Hrabcik, "Extension application to introduce a new pharmaceutical form associated with new

strength (2 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 1 year and above). The paediatric indication is applicable to the new presentation (2 mg/ml granules for oral suspension) as well as all approved presentations (EU/1/20/1500/001 and 002). The RMP (version 2.0) is updated in accordance.”

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

insulin human - EMEA/H/W/005779, Article 58 treatment of diabetes mellitus List of Questions adopted on 11.11.2021.
Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan, “Extension application to introduce a new strength 30/120/15 mg. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric indication: use in patients 2 years of age and older and weighing at least 14 kg. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.1) is updated in accordance.” List of Questions adopted on 14.10.2021.
dabigatran etexilate - EMEA/H/C/005639 prevention of venous thromboembolic events List of Questions adopted on 12.11.2020.
ertapenem - EMEA/H/C/005815 treatment of bacterial infections and prophylaxis of surgical site infection following elective colorectal surgery List of Questions adopted on 24.06.2021.
ganirelix - EMEA/H/C/005641 Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).

List of Questions adopted on 22.07.2021.

Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/X/0079/G
Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ilaria Baldelli, "Extension application to introduce a new strength (90 mg/90 mg/120 mg/6 mg film-coated tablets). The extension application is grouped with a type II variation (C.I.6.a) to include treatment of human immunodeficiency virus 1 (HIV 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg. Sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 5.1) is updated in accordance."
List of Questions adopted on 11.11.2021.

Ilumetri - tildrakizumab - EMEA/H/C/004514/X/0023
Almirall S.A, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski, "Extension application to introduce a new strength (200 mg solution for injection)."
List of Questions adopted on 11.11.2021.

insulin human - EMEA/H/W/005780, Article 58
treatment of diabetes mellitus
List of Questions adopted on 11.11.2021.

tebentafusp - EMEA/H/C/004929, Orphan
Immunocore Ireland Limited, treatment of uveal melanoma
List of Questions adopted on 09.11.2021.

molnupiravir - EMEA/H/C/005789
Treatment of coronavirus disease 2019 (COVID-19)
List of Questions adopted on 16.12.2021.

melphalan flufenamide - EMEA/H/C/005681, Orphan
Oncopeptides AB, treatment of multiple myeloma
List of Questions adopted on 16.09.2021.

pirfenidone - EMEA/H/C/005873
indicated in adults for the treatment of mild to

moderate idiopathic pulmonary fibrosis (IPF).
List of Questions adopted on 16.09.2021.

bevacizumab - EMEA/H/C/005574
treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.
First-line treatment of patients with advanced and/or metastatic renal cell cancer.
List of Questions adopted on 22.04.2021.

mitapivat - EMEA/H/C/005540, Orphan
Agios Netherlands B.V., treatment of pyruvate kinase deficiency
List of Questions adopted on 11.11.2021.

eptacog beta (activated) - EMEA/H/C/005655
treatment and for the prevention of bleeding
List of Questions adopted on 24.06.2021.

sitagliptin / metformin hydrochloride - EMEA/H/C/005850
treatment of type 2 diabetes mellitus
List of Questions adopted on 16.09.2021.

sugammadex - EMEA/H/C/005760
Reversal of neuromuscular blockade induced by rocuronium or vecuronium.
List of Questions adopted on 22.07.2021.

ranibizumab - EMEA/H/C/005610
treatment of neovascular age-related macular degeneration in adults
List of Questions adopted on 16.09.2021.

tezepelumab - EMEA/H/C/005588
add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma
List of Questions adopted on 14.10.2021.

Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0003/G
Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Sonja Hrabcik, "Extension application to add a new strength of 80 mg grouped with a type IB variation to add a new pack size for 40 mg

strength.
The RMP (version 1.2) is updated in accordance.
Furthermore, the PI is being brought in line with the QRD template version 10.2 to update the local representatives with "United Kingdom (Northern Ireland) "."
List of Questions adopted on 16.09.2021.

B.6.4. Annual Re-assessments: timetables for adoption

ELZONRIS - tagraxofusp - EMEA/H/C/005031/S/0012, Orphan
Stemline Therapeutics B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Orphacol - cholic acid - EMEA/H/C/001250/S/0042, Orphan
Laboratoires CTRS, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Sofia Trantza

SCENESSE - afamelanotide - EMEA/H/C/002548/S/0041, Orphan
Clinuvel Europe Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004240/R/0019
Mylan Pharmaceuticals Limited, Generic, Generic of Atripla (SRD), Rapporteur: Bruno Sepodes, PRAC Rapporteur: Martin Huber

Entecavir Accord - entecavir - EMEA/H/C/004458/R/0011
Accord Healthcare S.L.U., Generic, Generic of Baraclude, Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ulla Wändel Liminga

Entecavir Mylan - entecavir - EMEA/H/C/004377/R/0008
Mylan Pharmaceuticals Limited, Generic, Generic of Baraclude, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ulla Wändel Liminga

Fotivda - tivozanib -

EMEA/H/C/004131/R/0021
EUSA Pharma (Netherlands) B.V., Rapporteur: Bruno Sepodes, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Rugile Pilviniene

Koselugo - selumetinib - EMEA/H/C/005244/R/0003, Orphan
AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Annika Folin

Lacosamide Accord - lacosamide - EMEA/H/C/004443/R/0015
Accord Healthcare S.L.U., Generic, Generic of Vimpat, Rapporteur: John Joseph Borg, PRAC Rapporteur: Ulla Wändel Liminga

LIBTAYO - cemiplimab - EMEA/H/C/004844/R/0029
Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Menno van der Elst

LUTATHERA - lutetium (177Lu) oxodotreotide - EMEA/H/C/004123/R/0032, Orphan
Advanced Accelerator Applications, Rapporteur: Janet Koenig, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Adam Przybylkowski

Nexpovio - selinexor - EMEA/H/C/005127/R/0005
Karyopharm Europe GmbH, Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Menno van der Elst

Nitisinone MDK - nitisinone - EMEA/H/C/004281/R/0013
MendeliKABS Europe Limited, Generic, Generic of Orfadin, Rapporteur: Alar Irs, PRAC Rapporteur: Ilaria Baldelli

Rozlytrek - entrectinib - EMEA/H/C/004936/R/0007
Roche Registration GmbH, Rapporteur: Armando Genazzani, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/R/0040
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ana Sofia Diniz

Martins
Veklury - remdesivir - EMEA/H/C/005622/R/0031 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/R/0021, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, Co-Rapporteur: Egbert Flory, CHMP Coordinators: Johann Lodewijk Hillege and Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Adtralza - tralokinumab - EMEA/H/C/005255/II/0002 LEO Pharma A/S, Rapporteur: Jayne Crowe, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of adolescent patients (12-17 years) for Adtralza based on final study LP0162-1334 (ECZTRA 6): a multicentre, randomised, double-blind, placebo-controlled study in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis to evaluate the efficacy and safety of tralokinumab monotherapy in this population group. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance."
Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0002 BeiGene Ireland Ltd, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy, based on data from 88 patients with R/R MZL from 2 ongoing pivotal studies; study BGB-3111-214: A Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of zanubrutinib in patients

with R/R MZL, and study BGB-3111-AU-003: A first-in-human, Phase 1/2, dose-escalation and selection, PK/pharmacodynamic, safety, and efficacy study in adult patients with R/R or treatment-naive B-cell malignancies. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated, and the Package Leaflet is updated in accordance.
Version 1.1 of the RMP has also been submitted.
In addition, the MAH is requesting one additional year of market protection."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0014
Daiichi Sankyo Europe GmbH, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Evrysdi - risdiplam - EMEA/H/C/005145/II/0005/G, Orphan
Roche Registration GmbH, Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Jan Neuhauser, "Grouping of three variations as follows:
Extension of indication to include treatment of patients below 2 months of age based on interim results from study BN40703 (RAINBOWFISH). The pivotal study RAINBOWFISH is an ongoing phase II multicentre, open-label, and single-arm study designed to evaluate the efficacy, safety, tolerability, and PK/PD of risdiplam in pre-symptomatic infants below 2 months of age who were genetically diagnosed with SMA. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1

and 5.2 have been updated and the Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to make some editorial improvements in the product information. A revised RMP version 1.1 was also submitted as part of the application. Type IAIN, B.IV.1.a.1 As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance. Type IAIN, B.IV.1.b As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance."	
Fintepla - fenfluramine - EMEA/H/C/003933/II/0012, Orphan Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "Extension of indication to include treatment of seizures associated with Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted."	
GAVRETO - pralsetinib - EMEA/H/C/005413/II/0002/G Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Annika Folin, "Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, some minor changes to the PI have been implemented in line with the latest Anticancer Guidelines Recommendations. Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer for	

Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0070 Janssen-Cilag International NV, Rapporteur: Filip Josephson, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Nikica Mirošević Skvrce, "Extension of the existing CLL indication to include combination treatment with venetoclax for previously untreated patients based on efficacy and safety data from phase 3 study GLOW and phase 2 study CAPTIVATE. The SmPC is revised to reflect the information on the combination with venetoclax. The PL is updated accordingly. The RMP version 18.4 has been submitted. Justification to support one-year extension of the marketing protection period is included in the submission." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0041 AstraZeneca AB, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen, "Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, based on final results from study D419MC00004 (POSEIDON); This was a Phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy and safety of tremelimumab and durvalumab or durvalumab in combination with platinum based chemotherapy for first-line treatment in patients with metastatic NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8,	

5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2. Version 5.1 of the RMP has also been submitted."

LIBTAYO - cemiplimab - EMEA/H/C/004844/II/0028

Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include LIBTAYO in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations; as a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

Lynparza - olaparib - EMEA/H/C/003726/II/0053

AstraZeneca AB, Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli, "Extension of indication to include treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone, based on the results of the pivotal Phase III study PROpel (D081SC00001) and supportive evidence from Study 8 (D081DC00008). PROpel is a Phase III, randomised, double-blind, placebo-controlled, multicentre study evaluating olaparib vs placebo in combination with abiraterone as first-line treatment for men with mCRPC. Consequently, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC for Lynparza tablets are being updated. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on the updated safety data analysis. The Package Leaflet is updated accordingly. The RMP version 24 has also been submitted."

Lyumjev - insulin lispro - EMEA/H/C/005037/II/0014

Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Annika Folin, "Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above, based on final results from study I8B-MC-ITSB; this is a pivotal Phase 3 study designed to evaluate the safety and efficacy of Lyumjev compared to Humalog in combination with basal insulin in children and adolescent patients with T1D. The study was designed to compare change in HbA1c as the primary endpoint. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update minor editorial and linguistic changes in the SmPC and Package Leaflet.
As part of the application, the MAH is also requesting one additional year of market protection."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Revolade - eltrombopag - EMEA/H/C/001110/II/0068

Novartis Europharm Limited, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Extension of indication to include treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) irrespective of time since initial diagnosis, based on an ad-hoc analysis of study TAPER (CETB115J2411); an ongoing phase II, open-label, prospective, single-arm study in adult ITP patients who are refractory or relapsed after first-line steroids. As a consequence, sections 4.1 and 5.1 of the SmPC have been updated.
In addition, the MAH took the opportunity to make some minor amendments in section 4.8 of the SmPC for increased consistency.
An updated RMP version 54.0 has been submitted."

RINVOQ - upadacitinib - EMEA/H/C/004760/II/0016

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur:

Nikica Mirošević Skvrce, "Extension of indication to include the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation who have responded inadequately to NSAIDs or other conventional therapy, based on the final clinical study report from the pivotal study M19-944 study 2 (nr-axSpA); a randomized, double-blind, phase III study evaluating the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with nr-axSpA who completed the double-blind period on study drug. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. A revised RMP version 8.0 was also submitted."	
Ultomiris - ravulizumab - EMEA/H/C/004954/II/0026 Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of adult patients with generalized myasthenia gravis (gMG). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPC and package leaflet." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001 Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include treatment of infants, children and adolescents from 6 weeks to less than 18 years of age for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media for Vaxneuvance, based on final results from 1 Phase II study (V114-008) and 7 Phase III studies (V114-023, V114-024, V114-025, V114-027, V114-029, V114-030, V114-031);	

these are interventional studies to evaluate the safety, tolerability and immunogenicity of V114 in healthy and immunocompromised infants, children and adolescents. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include editorial changes in the product information. Version 1.1 of the RMP has also been submitted."	
WS2150 DuoPlavin- EMEA/H/C/001143/WS2150/0060 Iscover- EMEA/H/C/000175/WS2150/0146 Plavix-EMEA/H/C/000174/WS2150/0145 sanofi-aventis groupe, Lead Rapporteur: Bruno Sepodes, Lead PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Extension of indication to include clopidogrel in combination with acetylsalicylic acid in ST segment elevation acute myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI); as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. Version 1.5 of the RMP has also been submitted. In addition, an editorial update has been made to the labelling."	

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0030/G Baxalta Innovations GmbH, Rapporteur: Andrea Laslop	
Alymsys - bevacizumab - EMEA/H/C/005286/II/0007/G Mabxience Research SL, Rapporteur: Christian Gartner	
Azacitidine Accord - azacitidine - EMEA/H/C/005147/II/0009 Accord Healthcare S.L.U., Generic, Generic of Vidaza, Rapporteur: Hrefna Gudmundsdottir	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0090	See B.5.1

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0092/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0101 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0105 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COVID-19 Vaccine Janssen - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein - EMEA/H/C/005737/II/0040 Janssen-Cilag International N.V., Rapporteur: Christophe Focke	
Elaprase - idursulfase - EMEA/H/C/000700/II/0095 Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege	
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0024 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz	
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0025/G Seqirus Netherlands B.V., Rapporteur: Sol Ruiz	
Fulphila - pegfilgrastim - EMEA/H/C/004915/II/0029 Viatris Limited, Rapporteur: Martina Weise	
Hemlibra - emicizumab - EMEA/H/C/004406/II/0029/G Roche Registration GmbH, Rapporteur: Alexandre Moreau	
Ilumetri - tildrakizumab - EMEA/H/C/004514/II/0029/G Almirall S.A, Rapporteur: Jan Mueller-Berghaus	
Odomzo - sonidegib - EMEA/H/C/002839/II/0041 Sun Pharmaceutical Industries Europe B.V.,	

Rapporteur: Paula Boudewina van Hennik

Ogivri - trastuzumab - EMEA/H/C/004916/II/0040
Viatris Limited, Rapporteur: Karin Janssen van Doorn

Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0027
Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus

Pedea - ibuprofen - EMEA/H/C/000549/II/0030
Recordati Rare Diseases, Rapporteur: Jayne Crowe

Perjeta - pertuzumab - EMEA/H/C/002547/II/0063
Roche Registration GmbH, Rapporteur: Sinan B. Sarac

Regkirona - regdanvimab - EMEA/H/C/005854/II/0002
Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson

Respreeza - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0055/G
CSL Behring GmbH, Rapporteur: Kristina Dunder

Ruconest - conestat alfa - EMEA/H/C/001223/II/0071
Pharming Group N.V, Rapporteur: Andrea Laslop

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0038/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0046
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0050
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) -

EMEA/H/C/005791/II/0051/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus	
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0052/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus	
Supemtek - quadrivalent influenza vaccine (recombinant, prepared in cell culture) - EMEA/H/C/005159/II/0007/G Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus	
TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0002/G Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus	
TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0003 Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus	
Tysabri - natalizumab - EMEA/H/C/000603/II/0132 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0095 MCM Vaccine B.V., Rapporteur: Christophe Focke	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0061/G AstraZeneca AB, Co-Rapporteur: Johann Lodewijk Hillege	See B.5.1
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0062 AstraZeneca AB, Rapporteur: Sol Ruiz	
Votrient - pazopanib - EMEA/H/C/001141/II/0071/G Novartis Europharm Limited, Rapporteur: Sinan B. Sarac	

ZABDENO - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005337/II/0009/G
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege

WS2159/G
Prolia-EMEA/H/C/001120/WS2159/0095/G
XGEVA-EMEA/H/C/002173/WS2159/0079/G
Amgen Europe B.V., Lead Rapporteur: Kristina Dunder

WS2190
Lixiana-EMEA/H/C/002629/WS2190/0036
Roteas-EMEA/H/C/004339/WS2190/0023
Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro

WS2199
Infanrix hexa-EMEA/H/C/000296/WS2199/0311
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2218
Advate-EMEA/H/C/000520/WS2218/0115
ADYNOVI-EMEA/H/C/004195/WS2218/0029
Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2225/G
Abseamed-EMEA/H/C/000727/WS2225/0097/G
Binocrit-EMEA/H/C/000725/WS2225/0096/G
Epoetin alfa Hexal-EMEA/H/C/000726/WS2225/0096/G
Sandoz GmbH, Lead Rapporteur: Alexandre Moreau

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Caprelsa - vandetanib - EMEA/H/C/002315/II/0052
Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of section 4.4 of the SmPC in order to amend an existing warning on renal failure based on safety signal evaluation report.

In addition, the MAH took the opportunity to update the contact details for local representative in DE in the Package Leaflet.”	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0093 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information after booster dose, based on interim results from study C4591031, this is a randomized, placebo-controlled, phase 3 booster efficacy study involving participants ≥ 16 years of age who completed the primary series of BNT162b2 30 µg in study C4591001. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information.”	See 9.1 and B.5.2
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0102 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, “Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information 6 months post-dose 2 follow-up for adolescence 12 through 15 years of age based on updated interim results from study C4591001, listed as a specific obligation; this is a Phase 1/2/3, placebo-controlled, observer-blind, interventional, dose-finding, study to evaluate the safety, tolerability, immunogenicity and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. In addition, the MAH took the opportunity to implement minor editorial changes in section 6.3 of the SmPC and section 5 of the PIL of Comirnaty 30 micrograms/dose dispersion for injection.”	See B.5.2
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0104 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update immunogenicity, safety and efficacy information regarding heterologous vaccination (both in the primary series and for booster vaccinations) based on published literature data; the Package Leaflet is updated accordingly.	See 9.1

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information.”	
Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0053 MSD Vaccins, Rapporteur: Kristina Dunder, “Update of section 5.1 of the SmPC in order to update long-term effectiveness and immunogenicity data following the final results of the Gardasil 9 long-term follow-up (LTFU) study V503-002-20 listed as a category 3 study in the RMP. In addition, the applicant took the opportunity to make some minor editorial changes (spacings) and included the updated long-term follow-up data received for the qHPV vaccine following V501-167 extension study. The Package Leaflet is updated accordingly.”	
Glivec - imatinib - EMEA/H/C/000406/II/0129 Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, “C.I.4, Update of section 4.8 of the SmPC in order to add pemphigus with frequency rare and osteonecrosis with frequency uncommon to the list of adverse drug reactions based on an analysis of pre-clinical data, scientific literature, clinical trial datasets, Novartis pharmacovigilance database, EVDAS and other safety databases. The Package Leaflet is updated accordingly. The MAH is also taking the opportunity to align section 4 of the PL with the already approved ADR section of the SmPC as a number of ADRs is not reflected accurately.”	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0039/G AstraZeneca AB, Rapporteur: Sinan B. Sarac, “Update of section 4.2 of the SmPC in order to update the recommendation for dose modification for the adverse reaction myocarditis based on NCCN guideline recommendations (2021) and findings in a Global Patient Safety Database, and update of section 4.8 of the SmPC to further clarify the medical concept of the adverse reaction encephalitis, by revising the footnote of the ADR table for encephalitis.”	

Imfinzi - durvalumab - EMEA/H/C/004771/II/0040

AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Update of section 5.1 of the SmPC in order to update efficacy data based on the results of the 5-year follow-up analysis of the PACIFIC study (a randomised, double blind, placebo controlled, multicentre study in patients with locally advanced, unresectable NSCLC). In addition, the MAH took the opportunity to include analyses of the exploratory endpoints to meet the commitment (recommendation) to submit exploratory analyses from the PACIFIC study."

MenQuadfi - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/005084/II/0013

Sanofi Pasteur, Rapporteur: Andrea Laslop, "Update of section 5.1 of the SmPC in order to add data on the immunogenicity of serogroup C based on the final results from study MEQ00065; this is a study to compare the immunogenicity and safety of serogroup C of a single dose of Menquadfi to Nimenrix or NeisVac in meningococcal naïve toddlers 12-23 months of age."

Mosquirix - plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0060

GlaxoSmithkline Biologicals SA, Rapporteur: Jan Mueller-Berghaus, "Submission of the final study report from study Malaria-073, a Phase III, randomized, open-label, controlled and multicentre study that addressed two safety concerns listed in the RMP: immunogenicity when coadministered with yellow fever and measles vaccines, and cross-immunisation against human catalase. The submission of the study addresses MEA 004."

Orphacol - cholic acid - EMEA/H/C/001250/II/0044, Orphan

Laboratoires CTRS, Rapporteur: Anastasia Mountaki, "Update of sections 4.3 and 4.5 of the SmPC in order to extend the currently existing contra-indication with phenobarbital in order to include primidone based on scientific literature. The Package Leaflet is updated accordingly. In addition, the MAH is also taking this opportunity to submit a combined SmPC for

both dosages, 50 mg and 250 mg and to introduce editorial changes and update the contact details of the local representatives in the Package Leaflet."

Orphacol - cholic acid - EMEA/H/C/001250/II/0045, Orphan
Laboratoires CTRS, Rapporteur: Anastasia Mountaki, "Update of section 4.5 of the SmPC in order to update the existing information regarding concomitant use of cholic acid (the active substance of Orphacol) and ursodeoxycholic acid based on scientific literature. The Package Leaflet is updated accordingly."

QINLOCK - ripretinib - EMEA/H/C/005614/II/0002, Orphan
Deciphera Pharmaceuticals (Netherlands) B.V., Rapporteur: Filip Josephson, "Submission of the final report from study XT218029 (DP-4851: ABC Transporter Substrate Potential in Cells). This submission fulfils the PAM commitment "New in vitro experiment to study whether ripretinib is a substrate of BCRP, which follows the design outlined in appendix 3 of the DDI GL - October 2021-REC."

Repatha - evolocumab - EMEA/H/C/003766/II/0058
Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "C.I.4 Update to section 5.1 of the SmPC following the results of interventional study 20160184.
It was a double-blind, placebo-controlled, randomized study evaluating the effect of evolocumab on coronary atherosclerotic plaques as assessed by optical coherence tomography (OCT) following 50 weeks of treatment in subjects with non-ST-elevation acute coronary syndrome (NSTE-ACS) who take maximally tolerated statin therapy."

Roclanda - latanoprost / netarsudil - EMEA/H/C/005107/II/0002
Aerie Pharmaceuticals Ireland Limited, Rapporteur: Jayne Crowe, "C.I.4, Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study PG324-CS303; this is a prospective, double-masked, randomized, multicentre, active-controlled, parallel-group, 6-

month study assessing the safety and ocular hypotensive efficacy of Roclanda compared to bimatoprost + timolol in subjects with elevated intraocular pressure that was insufficiently controlled and/or deemed to be in need of combination IOP-lowering therapy. The Package Leaflet is updated accordingly."	
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0047 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of section 5.1 of the SmPC in order to introduce data on the immunogenicity of Spikevax against the B.1.617.2 (Delta) variant in adults and children, based on cross-neutralisation data from studies mRNA-1273-P301 (an ongoing Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older - NCT04470427), mRNA-1273-P201B (Part B of an ongoing Phase 2a, Randomized, Observer-Blind, Placebo-Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older - NCT04405076), and mRNA-1273-P204 (an ongoing Phase 2/3, 2-part, open-label, dose-escalation, age de-escalation and subsequent randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 in healthy children - NCT04796896)."	See 9.1
Tivicay - dolutegravir - EMEA/H/C/002753/II/0077 ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Following the recommendation (REC) requested during the procedure EMA/H/C/2753/X/58G, the MAH submits the manuscript of the ODYSSEY study which contains efficacy and long-term safety results to 96 weeks for Tivicay tablets. This study an open-label, multicentre, randomized (1:1), non-inferiority, Phase II/III, 96-week, 2-arm clinical trial to compare the efficacy and toxicity of dolutegravir (DTG) plus 2 NRTIs vs. standard of care in HIV infected children aged less than 18	

years who are starting first-line ART (ODYSSEY A) or switching to second-line ART (ODYSSEY B). Based on the results no amendments to the product information for DTG (Tivicay) are considered warranted and therefore, no updated SmPC is provided as part of this application."	
Trogarzo - ibalizumab - EMEA/H/C/004961/II/0018 Theratechnologies Europe Limited, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC in order to add additional efficacy data based on results from study TMB-311, a multicentre, expanded access phase 3 study providing post-hoc long-term data on patients from study TMB-301."	
Trumenba - meningococcal group b vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0037 Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 of the SmPC in order to include immunopersistence and booster data based on final results from study B1971035 listed as a part of the paediatric investigation plan; this is a phase 2, randomized, controlled, observer-blinded study conducted to describe the immunogenicity, safety and tolerability of Bivalent rLP2086 when administered to healthy toddlers aged 12 to <18 months or 18 to <24 months, and the safety and immunogenicity of a booster dose of Bivalent rLP2086."	
Xarelto - rivaroxaban - EMEA/H/C/000944/II/0093 Bayer AG, Rapporteur: Kristina Dunder, "Update of section 5.1 and subsequent changes in sections 4.2 and 4.8 based on final results from study 18226 (UNIVERSE); this is a prospective, open-label, active controlled, multicentre, 2-part study, designed to evaluate the single- and multiple-dose pharmacokinetic properties of rivaroxaban (Part A), and to evaluate the safety and efficacy of rivaroxaban when used for thromboprophylaxis for 12 months compared with acetylsalicylic acid (Part B) in children 2 to 8 years of age with single ventricle physiology who had the Fontan procedure. In addition, the MAH took the opportunity to introduce editorial changes to sections 4.8 and	

4.9 of the SmPC.”
Xtandi - enzalutamide - EMEA/H/C/002639/II/0058 Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, “Update of section 4.5 in order to add information regarding drug-drug interaction based on final results from study 9785-CL-0018. - A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects with Prostate Cancer. Additionally, the MAH has taken the opportunity to make an update to the information about the excipients in section 4.4 of the SmPC, to introduce editorial changes in the SmPC and in the Package Leaflet, and to update the list of local representatives in the Package Leaflet.”
WS2224 Eucreas- EMEA/H/C/000807/WS2224/0094 Galvus-EMEA/H/C/000771/WS2224/0075 Icandra- EMEA/H/C/001050/WS2224/0097 Jalra-EMEA/H/C/001048/WS2224/0077 Xiliarx-EMEA/H/C/001051/WS2224/0075 Zomarist- EMEA/H/C/001049/WS2224/0096 Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, “Update of section 4.8 of the SmPC in order to update the list of ADRs and update the ADR table in line with the EC SmPC guideline (2009). The Package Leaflet is updated accordingly.”

B.6.10. CHMP-PRAC assessed procedures

ADCETRIS - brentuximab vedotin - EMEA/H/C/002455/II/0099, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.8 and 5.1 of the SmPC, based on final results from study C25006, a multicentre open-label, phase 4 study of 50 patients with r/r sALCL undertaken to further evaluate the efficacy and safety of brentuximab vedotin as a single agent

in adult patients who had previously received at least 1 multiagent chemotherapy regimen. This study is listed as an interventional cat 2 PASS in the RMP (SOB 010). In addition, the MAH took the opportunity to delete SOB 010 from the annex II and to delete the mention of conditional approval from annex II and the package leaflet. The RMP version 16.1 has also been submitted."

Afstyla - lonoctocog alfa - EMEA/H/C/004075/II/0042

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 3001 listed as a category 3 study in the RMP; this is an open label, multicentre extension study to assess the Safety and Efficacy of Afstyla in subjects with severe Haemophilia A. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 6.0 has also been submitted."

ASPAVELI - pegcetacoplan - EMEA/H/C/005553/II/0002, Orphan

Swedish Orphan Biovitrum AB (publ), Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kimmo Jaakkola, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on final results from study APL2-302 (Pegasus) listed as a category 3 study in the RMP; this is a global, Phase 3, prospective, randomised, multicentre, open-label, active-comparator–controlled study in 80 subjects. The objective was to confirm treatment efficacy and safety of pegcetacoplan monotherapy for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The submission of this study addresses MEA 001.The Package Leaflet is updated accordingly. The RMP version 0.5 has also been submitted."

Dexdor - dexmedetomidine - EMEA/H/C/002268/II/0035

Orion Corporation, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.4 of the SmPC in order to add a new warning on Mortality in ICU patients ≤ 65 years old, based on results from study SPICE III (randomised controlled trial) and following the

assessment of the post-authorisation measure LEG 16.4. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.
The RMP version 9, a proposed DHPC and communication plan have also been submitted."

Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/II/0010, Orphan
Novo Nordisk A/S, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski,
"Update of sections 4.4 and 4.8 of the SmPC to add a new warning and update the list of ADRs based on a validated safety signal concerning a lack of factor VIII activity in patients switching from a similar factor VIII product to Esperoct. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to align it with the latest QRD template version 10.2. The RMP version 2.0 has also been submitted."

Fintepla - fenfluramine - EMEA/H/C/003933/II/0010/G, Orphan
Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber,
"- Update of section 5.3 of the SmPC in order to update the non-clinical information following the study 20147822 (A 6-month Carcinogenicity Study of Fenfluramine Hydrochloride in Mice).
- Update of section 5.3 in order to update the non-clinical information following the study 8001993 (A 2-year Oral Gavage Carcinogenicity Study of Fenfluramine Hydrochloride in Rats).
- Submission of the final report of study 20147821 (Dose range finding study for 20147822).
- Submission of the final report of study 20166554 (Dose range finding study for 20147822).
- Submission of the final report of study 2021006-Z001-01 (In-vitro Evaluation of Potential Melanin Binding by Fenfluramine and Norfenfluramine).
An RMP version 3.1 has also been submitted."

Fintepla - fenfluramine - EMEA/H/C/003933/II/0011/G, Orphan
Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber,
"- Update of sections 4.2 and 5.2 of the SmPC

to include the relevant information regarding patients with renal impairment following the study 1902 (Pharmacokinetic study of fenfluramine hydrochloride in subjects with varying degrees of impaired and normal renal function). - Update of sections 4.4 and 4.5 of the SmPC in order to reflect the relevant information on CYP1A2 or CYP2B6 or CYP2D6 inducers following the study 1904 (Pharmacokinetic drug-drug interaction study of fenfluramine hydrochloride with and without fluvoxamine (CYP1A2 inhibitor), paroxetine (CYP2D6 inhibitor) and rifampin (CYP2B6 inducer) in healthy subjects). An RMP version 2.2 has also been submitted."	
MabThera - rituximab - EMEA/H/C/000165/II/0188 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, "Submission of the final report from study MA28150 (RITAZAREM) entitled Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophilcytoplasm antibody-associated vasculitis listed as an interventional category 3 study in the RMP. The RMP version 23.0 has also been submitted."	
Myalepta - metreleptin - EMEA/H/C/004218/II/0025, Orphan Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam Przybylkowski, "Submission of an updated RMP version 2.1. The applicant is proposing an alternative study to the currently agreed protocol for Specific Obligation SOB002 (AEGR-734-002) due to the challenges of implementing the existing protocol. Annex II is being updated accordingly. The MAH took the opportunity to update the RMP in line with the outcome of previous procedures and to include editorial changes."	
Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056 Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess	

the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly."	
Oxlumo - lumasiran - EMEA/H/C/005040/II/0008, Orphan Alnylam Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to clarify administration instructions, remove an existing warning on metabolic acidosis in patients with severe or end stage renal impairment, update the description of adverse reactions injection site reactions, abdominal pain and immunogenicity, update efficacy, pharmacokinetic information based on interim results from a category 3 study in the RMP ILLUMINATE-C (ALN-GO1-005): A single arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) and, in addition, based on available long-term efficacy and safety data from ongoing phase 3 studies ALN-GO1-003 in PH1 patients >6 years old and ALN-GO1-004 in PH1 patients <6 years old, and open-label extension study ALN-GO1-002. The Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted."	
Pemazyre - pemigatinib - EMEA/H/C/005266/II/0005, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study INCB054828 (FIGHT-202) listed as a specific obligation in the Annex II (SOB/002); this is a phase 2 study investigating the efficacy and safety of pemigatinib in adults with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy. The Annex II has been updated accordingly. RMP version 2.0 has also been submitted."	
Prolia - denosumab - EMEA/H/C/001120/II/0093	

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2 and 4.4 of the SmPC in order to change the posology recommendation for paediatric population and add a new warning on hypercalcaemia in paediatric patients with osteogenesis imperfecta following an urgent safety measure regarding the risk of hypercalcaemia reported very commonly in ongoing clinical trials in paediatric patients with osteogenesis imperfecta (OI) treated with denosumab; the Package Leaflet is updated accordingly. The RMP version 29.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to implement minor editorial changes in the Labelling."

Raxone - idebenone - EMEA/H/C/003834/II/0031, Orphan

Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli, "Update of sections 4.2, 4.4, 4.9 and 5.1 of the SmPC based on the final study report from the PAROS study SNT-IV-003 (SOB003; listed as a cat 2 study in the RMP): "A non-interventional study of clinical experience in patients prescribed Raxone for the treatment of Leber's Hereditary Optic Neuropathy (LHON)". Annex II is updated in accordance. A revised RMP version 1.14 was also submitted."

Replagal - agalsidase alfa - EMEA/H/C/000369/II/0117

Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.2 and 6.6 of the SmPC in order to add self-administration by a trained patient and/or a caregiver as a new method of administration. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. The RMP version 0.1 has also been submitted."

RINVOQ - upadacitinib - EMEA/H/C/004760/II/0015/G

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Grouping of 2

variations:
C.I.4 - Update of sections 4.8 to add neutropenia and 5.1 of the SmPC in order to update efficacy information of Rinvoq in Ankylosing Spondylitis (AS) patients who are biologic DMARD inadequate responders (bDMARD-IR) based on interim results from study M19-944 study 1; this is a Phase 3, randomized, double-blind, study evaluating the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with active AS who have an inadequate response (IR) to bDMARD.
C.I.4 - Update of section 5.1 of the SmPC in order to include long-term (through week 104) data in AS patients who are naïve to previous treatment with a bDMARD based on interim results from study M16-098; this is a Multicentre, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis;
The RMP version 7.0 has also been submitted.
In addition, the MAH took the opportunity to introduce minor editorial changes in the product information."

Rydapt - midostaurin - EMEA/H/C/004095/II/0024, Orphan
Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.11.b Submission of the final report from study CPKC412E2301 listed as an obligation in the Annex II of the Product Information. This is a Phase III study to investigate the efficacy in elderly patients. A final pharmacogenomic report is also provided to fulfil MEA004. The Annex II and the RMP (submitted version 7.0) are updated accordingly."

Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0006
Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Submission of the final report from study MVT-601-035 listed as a category 3 study in the RMP. This is an international phase III double-blind, placebo-controlled, randomised withdrawal study of relugolix co-administered

with estradiol and norethisterone in women with heavy menstrual bleeding associated with uterine fibroids to evaluate the efficacy and safety of long-term use of this medicinal product. The RMP version 1.0 has also been submitted."

WAYLIVRA - volanesorsen - EMEA/H/C/004538/II/0017/G, Orphan

Akcea Therapeutics Ireland Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "C.I.4: Update of sections 4.8 and 5.1 of the SmPC based on the final results from study (ISIS 304801 CS7), a multicentre open label extension study of Volanesorsen administered subcutaneously to patients with Familial Chylomicronemia Syndrome. The Package Leaflet has been updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI in order to align with the QRD template and to introduce minor linguistic update to Annex III of the product information to support product launch. C.I.11b. for RMP: Submission of an updated RMP version 2.1 based on the clinical study report addendum: A randomized, double blind, placebo-controlled Phase 3 study of ISIS 304801 administered subcutaneously to patients with Familial Chylomicronemia Syndrome (ISIS 304801 CS6 (APPROACH).
C.I.11b. for RMP: Submission of an updated RMP version 2.1 in order to update section V.2 Additional Risk Minimisation Measures in the RMP to reflect a change in the distribution methodology of the educational materials (from a centralised model to a localised model of distribution) and to clarify what is meant by the prescriber kit.
C.I.13: Submission of the final report from study ISIS 304801 (CS17). This is a Phase 2/3 double blind, randomized, placebo-controlled study, with an open label extension of ISIS 304801 administered subcutaneously to patients with familial partial lipodystrophy. The RMP version 2.1 has also been submitted."

Xtandi - enzalutamide - EMEA/H/C/002639/II/0057

Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva

A. Segovia, "C.I.4
Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to reflect the updated safety and efficacy data from the final analysis of the 9785-CCL-0335 (ARCHES) study, a phase 3 randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with mHSPC; the Package Leaflet is updated accordingly. The RMP version 17.0 has also been submitted. In addition, the MAH took the opportunity to make minor editorial changes to section 4.8 and section 5.1 of the SmPC."

B.6.11. PRAC assessed procedures

PRAC Led
Cyramza - ramucirumab - EMEA/H/C/002829/II/0047
Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study I4T-MC-JVDD listed as a category 3 study in the RMP for Cyramza, entitled 'Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (Study I4T-MC-JVDD)' (Related to MEA 001.1). The RMP version 10.1 has also been submitted. "

PRAC Led
Inflectra - infliximab - EMEA/H/C/002778/II/0105
Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of the final report from study CT-P13 4.2; An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Inflectra in Patients with Rheumatoid Arthritis (study report excluding the joint analysis of patients in the PERSIST study). The submission of the study report addresses MEA 007.6."

PRAC Led
Kuvan - sapropterin -

EMEA/H/C/000943/II/0073

BioMarin International Limited, Rapporteur: Peter Kiely, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Submission of the final report from study BMN 162-501 KAMPER (formerly EMR700773-001) listed as a category 3 study in the RMP. This is an observational drug registry to assess the long-term safety in subjects treated with Kuvan. The submission of this study addresses the PAM MEA 020. The RMP version 15.1 has also been submitted."

PRAC Led

Latuda - lurasidone -

EMEA/H/C/002713/II/0037

Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Filip Josephson, "Submission of an updated RMP version 9.0, based on the implementation of the PASS outcome (EMEA/H/C/002713/II/0033), to remove from the list of safety concerns of important identified risks and important potential risks; and to discontinue the use of targeted adverse event follow-up questionnaire for angioedema."

PRAC Led

Moventig - naloxegol -

EMEA/H/C/002810/II/0038

Kyowa Kirin Holdings B.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Submission of an updated RMP version 7.2 proposing the cancellation of the cat. 3 study (D3820R00009: An Observational Drug Utilisation PASS of Moventig in selected European populations), following the assessment of MEA 006.11"

PRAC Led

Praluent - alirocumab -

EMEA/H/C/003882/II/0068

sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC, based on the final results from category 3 study OBS14697; a non-interventional, retrospective drug utilisation study that was designed to assess in Europe the effectiveness

of the dosing recommendation and to describe patterns of alirocumab utilization in real world clinical practice. In addition, the MAH took the opportunity to implement editorial changes in SmPC and package leaflet. The submission of the study report addresses the Post-Authorisation Measure MEA/FSR 019.8."

PRAC Led

Remsima - infliximab - EMEA/H/C/002576/II/0111

Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of the final report from study CT-P13 4.2; An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients with Rheumatoid Arthritis (study report excluding the joint analysis of patients in the PERSIST study). The submission of the study report addresses MEA 007.6."

PRAC Led

XALKORI - crizotinib - EMEA/H/C/002489/II/0075

Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report for non-interventional PASS cat 3 study A8081062, a descriptive study of potential sight threatening event and severe visual loss following exposure to crizotinib (related to MEA 024)."

PRAC Led

Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0033

Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)."

PRAC Led

WS2210

Dovato-EMEA/H/C/004909/WS2210/0028

Juluca-EMEA/H/C/004427/WS2210/0041
Tivicay-EMEA/H/C/002753/WS2210/0076
Triumeq-
EMEA/H/C/002754/WS2210/0100

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Ingrid Wang, "Following the finalisation of procedure EMEA/H/C/WS1810 concerning submission of EUROSIDA (category 3 PASS) study, this type II work-sharing variation is now proposed to address the removal of 3 identified risks (Dolutegravir Hypersensitivity reactions, Hepatobiliary reactions and Serious rash) from all 4 dolutegravir-containing product EU-RMPs; Tivicay (dolutegravir), Triumeq (dolutegravir/abacavir/lamivudine), Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) - i.e. deletion of safety concerns.
In addition, the MAH take opportunity to propose a harmonisation of the risks across all 4 dolutegravir-containing product EU-RMPs and other minor updates (including study details and epidemiology data), which the MAH considers can be included as part of an RMP update without the need for an additional variation scope as per EMA post-authorisation guidelines."

PRAC Led
WS2212
Effentora-
EMEA/H/C/000833/WS2212/0060

Teva B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP version 5.1 in order to reformat the RMP according to the revised guidance on GVP Module V (revision 2) and to implement PRAC comments arising from previous assessments as follows:
- Revision of the list of safety concerns;
- Implementation of key messages in educational materials adopted by PRAC for Instanyl;
- Revision of Annex 6 to include verbatim the text adopted by PRAC for Instanyl as presented in Annex 2 of the PRAC PSUSA AR;
- Revision of the use of digital access to educational material;

- Explanation of the role of the Health Products Regulatory Authority (HPRA)'s CAPA being no longer found to be a trigger of the current RMP update.
The 'additional risk minimisation measures' in the Annex II of the product information have been updated accordingly."

PRAC Led
WS2214
Duloxetine Mylan-
EMEA/H/C/003981/WS2214/0029
Mylan Pharmaceuticals Limited, Generic, Generic of Cymbalta, Lead PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "To update the RMP in order to align with the originator.
The MAH has taken the opportunity to amend the RMP template GVP Module V Rev.2, where required, and to achieve one RMP covering multiple different marketing authorisations procedures containing the same active substance for which Mylan has an approved RMP.
The RMP is also updated with the results of a follow-up up questionnaire pertaining to suicidality as recommended in the Renewal EMEA/H/C/003981/R/0021."

PRAC Led
WS2216
Exviera-EMEA/H/C/003837/WS2216/0052
Maviret-
EMEA/H/C/004430/WS2216/0049
Viekirax-
EMEA/H/C/003839/WS2216/0064
AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)."

PRAC Led
WS2222
Epclusa-
EMEA/H/C/004210/WS2222/0064

Harvoni-
EMEA/H/C/003850/WS2222/0104
Sovaldi-EMEA/H/C/002798/WS2222/0077
Vosevi-EMEA/H/C/004350/WS2222/0054
Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)."

B.6.12. CHMP-CAT assessed procedures

Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0048, ATMP
Amgen Europe B.V., Rapporteur: Heli Suila, CHMP Coordinator: Johanna Lähteenvuo, "Update of section 4.4 of the SmPC in order to add a new warning about the potential risk of hepatic haemorrhage with the transcutaneous intrahepatic route of administration of talimogene laherparepvec. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0049/G, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0024, Orphan, ATMP
Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

WS2197
Tecartus-
EMEA/H/C/005102/WS2197/0017
Yescarta-
EMEA/H/C/004480/WS2197/0047
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan

Mueller-Berghaus

B.6.13. CHMP-PRAC-CAT assessed procedures

Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/II/0033, Orphan, ATMP
Orchard Therapeutics (Netherlands) BV, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst, "Submission of the final report from study STRIM-001 "Evaluation of referring healthcare providers' and parents'/carers' understanding of specific risks associated with Strimvelis treatment" listed as a category 3 study in the RMP. The RMP version 6.1 has also been submitted."

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and work-sharing procedures of type I variations

WS2168
Lyrica-EMEA/H/C/000546/WS2168/0114
Pregabalin Pfizer-
EMEA/H/C/003880/WS2168/0043
Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, "To update SmPC sections 4.4 and 4.8 to reflect new data on suicidal ideation following the review of the data provided in LEG 007 and 054. The package leaflet has been updated accordingly."

WS2213/G
Aprovel-
EMEA/H/C/000141/WS2213/0189/G
Karvea-
EMEA/H/C/000142/WS2213/0191/G
sanofi-aventis groupe, Lead Rapporteur: Maria Concepcion Prieto Yerro

WS2220/G
Cymbalta-
EMEA/H/C/000572/WS2220/0088/G
Duloxetine Lilly-

EMEA/H/C/004000/WS2220/0025/G
Yentreve-
EMEA/H/C/000545/WS2220/0073/G
Eli Lilly Nederland B.V., Duplicate, Duplicate of Ariclaim (SRD), Yentreve, Lead Rapporteur: Maria Concepcion Prieto Yerro

WS2221/G
Eucreas-
EMEA/H/C/000807/WS2221/0093/G
Galvus-
EMEA/H/C/000771/WS2221/0074/G
Icandra-
EMEA/H/C/001050/WS2221/0096/G
Jalra-
EMEA/H/C/001048/WS2221/0076/G
Xiliarx-
EMEA/H/C/001051/WS2221/0074/G
Zomarist-
EMEA/H/C/001049/WS2221/0095/G
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder

WS2228
Eucreas-
EMEA/H/C/000807/WS2228/0095
Icandra-
EMEA/H/C/001050/WS2228/0098
Zomarist-
EMEA/H/C/001049/WS2228/0097
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. Time-Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 24-27 January 2022 CHMP plenary:

Psychiatry	
Treatment of Major Depressive Disorder (MDD) (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Endocrinology-Gynaecology-Fertility-Metabolism	
Treatment of type 1 diabetes mellitus (TlD) (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Auto-inflammatory diseases	
haemophagocytic lymphohistiocytosis (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Oncology	
Treatment of paediatric patients with diffuse intrinsic pontine glioma (SME)	The CAT and the CHMP denied eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in January 2022 for February 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address